var title_f13_7_13424="Rounded protracted shoulder posture";
var content_f13_7_13424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posture with rounded and protracted shoulders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posture shown in the photograph, with the shoulders rounded and protracted, is common among those who spend a great deal of time working at a desk. In such cases, it is often associated with dysfunction of the scapular stabilizing muscles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13424=[""].join("\n");
var outline_f13_7_13424=null;
var title_f13_7_13425="ERC anastomosis stricture";
var content_f13_7_13425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Severe anastomotic stricture in the distal biliary tract following liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 319px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE/AesDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1HVNRu49Su1W7uAomfA8w8DJqgmtT3Typb6jK7Rna4WckqfQ88VD4uvRp41e9kjaRbcyy+Wgyz4ycD3PSvF/hXBrWh+LLSbVtNu4IvENu8k0rurq04ZpFfCklBsbbhsHJ/CgD3EX96GwL26z/ANdW/wAatxXV+VBN3cHP/TVv8aqRQjeM9etXAdmKALaXd2qEtc3GfTzDSfbbssD9qnA/66GowSw9qiaREGQckUAWze3Kglrqf/v4aqzapeEYW6n/AO/hqrJI0nXPPahVI5YUATjUb0AZu5/+/h/xpovr5ycXdwB/11b/ABqF9nrz6U4gLDnvQBHcX16MgXtyP+2rf41Cl/ftz9tusdP9a3+NRTtz7j9ajg3Y3PwD0FACz3+pGTCX90B/12b/ABqvcahqCNj+0Lzgf89m/wAakYZk4ont17jLH3oArjUNUZAF1C8JHX983+ND6hqKqCNSuz/23bj9anWIIjbRzUDQBsZHX0oArrqWpByf7RvW/wC27f41NNquobVVdQvA3f8Aftz+tMjgA3HOMdagdRvLkjNADbjUNYJAGo3qoOeJ2/xrP1jWNVjsxs1O/HPUXD/41rpMm12YBmA4rntVbzYiij3oAxv7c1tpRt1fUgB3N0/+NSXPiHWIUKjV9QLf9fL/AONUTGUkbJJPpVGaJ8sW4zQBsDXNcMYY6zqA9vtT/wCNNHijWmkWP+1tQwOv+kv/AI1jbhEBuO6kjkHnoAuSTzQB1A8QaxwzarqGAf8An5f/ABqnceJ9VkmZI9Y1Fcely/8AjVS4uCBsVciqtvAizBmXLE9BQBsjW9dEBJ1bUST0/wBKf/GqSa54gjcCXWNS+bt9qf8Axp23czBAcD9KlihTyi7sC4+6KANey1/V+BJqd+cDk/aH/wAauza/qIaJU1O+ye/2h/8AGufgc4K4AHrV63jQuGZxkDIFAHcaZe6iYEaXUbsD3nbP867nR72aTTY2+0SseRkuSeteRx3r4AYkivRfCcu7S4c9Dn+dAG1b65bS3XkR6pDJPkjyluAWyOoxnNbMFxKQMyPz7mvj200+b/hI2MOnrdajD4pa6jtY9LlS5ljEvX7WBtEffb7Zr67jVlOOuO9AGoJmAHzE/jSec7ngn86qo2B8xz7Uoc7uOlAGlDISAGY1LFJknLVnK/HXkVZgbJJIoAu55NLnmoFl3HsO1DyIvfJoAnzQWAGaqGUtjHFRu23POaALu/cMilB5qoknTmp0PzckUATUUZooAQ9aGOBSA/MaVulADYwcEsabIzdQRimvL8vAqPBYZPGKAHo5LHJzj0NRO5BOGI/Gh3VFwoznvVd3LdeBQArzuOAx+uahaWQHh3596U8980Y4zxzQBG0krD/WMPxqFnlU5E0jf8CNTshYEjmkWFvXg9qAIvOk2DDybj/tGoWNzuy00gH+8avCEAZLY9qimTecA8UAVR5shwLiT3O81l3r3iSlEuZiPXea05IWhbdnIpzwL5e/GWNAGIl5cqyj7RMfq5rqNJld9PiZnck55JJ7mufltsklQN306Vu6NGy6bCrHkbv/AEI0Aefaom7Vbv085/8A0I0kMZC5Iq5qEYGpXZ/6av8AzNR4CjoTQA14+ARU0URbBbpURZip7CpLaTggt8ooAju2ZCQp49aqKp6HJBqxdNmQADKmowcDHFAD4xzk9BSzOSPlBFKThFB70yQgqQM5/nQBWkQuQE4agB1Uh2z6VMgPVeKYQTwOtAFdo/mywq5bWcU0bfPhuwpFt2ON1K5MTLs6igCqlsYpTvPOaSSPk4GCO9XLkbnjYk5YZqFgcEjkjigCquRE27rUPzFuMe1WCpwc85pmFGSpyR2FAFS5TZE3zZJOTWeY2KEg8HtVm4Zy5BGBnjNMdCqgA5z6UAUnUhMqee9UJQCGAOc5ya1ZLd5In2jkd6yrgeUPlBPY0AYs0TKSMVkXKkSPnJrqjbM+HKkZ6Vm3UEMG4n5j1NAHOyW8kigIpGe5rQsba3gG64lG8DpVa6upWYrGCM8ACmR27K+Zclhyc0Aa0cX2qUtGwKD060tyjRMFVcZ70zSS6SgkcnoKtapKC48zAwOlADLceUXB+YsOTVWNSZT84A9DUkcgWIHr3qoW82QkDaaALIcmTZj5R3qxbK5cHBC1mpMd5B4rRtnkZMHhfWgDetRuX5gAK9I8MKw0qArjHP8AOvMrEl5EUnvXqGg4XTolXoM0AdDaOBgMMmtMndGDmsOF8da0LWfbwaAJweDSo5BwSKVhkfKQaj+6ct1oAmVsEHqKtRSYTnr7VnCUnjGBU6t8uRQBNJcFWwO9KHLDnk1VYjOR1qWNs+1AFpWK44oL9ccmow2MY70in+9QBMj56gVZi5dc9uarR4IzxViJtucjIoAtkkAd6Y+duacrAjimtl8Y45oAEbCZxyKQNuJJOBTXcKCByfWoGYnnH1oAmkkAI2gHFRF2fr0FIoyDmkPFAEMjHJz17VGSSMVKw3D39KVIiBk8UARnoBinMhx7U/aMg4oYYzQAiLgelOlkWMccsaZnJwKQJljuFADS+9Tk5pq8np1qVV2gE96YzKD/AJ5oAaIkdgW5AqK9II2pxT3uAinA47VTEhY5C5JoANqwRb2GWPArS00g2UZHTn+ZrHnds7X7dq1dLKmxjxjv/M0AcRqbAX91t6+a+fzNVS21CerGl1WULqV2FOf3r5/M1R3nGN3FAE6yYHzHrTFbcTtPGajXk80o+UllPHfNAEqkmUbs4FK8e7pwajTls9c1N90A7qAGkMTtPbvTyAGweopxBK5XrUlugb73JFADUiyBnpRsRcnFWmIGB2phCgE0AQMD26VFsLNjGeamJyeP0ojG1WZjjFAEV2AZgAcYHrVaRiiEjOTUnEk24k1HI4ZiB0oAquSEBJxmmQvtc4GT61O8W58daWaIQpkYyRQBjylnmLMeM9KsxxD77NwOahaJ3c7eeelWZo2CbEOOMUAVfNwXCHg1QljG8+g5qzIvlgg43etQBiUYnk9KAKV1K4AHAz2rKmtmkU8cnua3TaGQhsc+9Sy2/AAA5GMCgDjfsyxyDIB9TUU+3zGIU4re1LTPsv7ydwO4ArCnkADHjJ6ZoAZFI2cocAdTVK9kdnJYk1YSTZ8pIJb07VBchT8x7cUALYSHpIcLSyv5lzsLbUB6is+WXaV2nirBUiLcx+lADjgSkK2ecA1pWBdvkLcDnNYiMGfLHkVv6ZgKGNAHU6NFGcFzk9jXe6Y2y2jA9685spCjKVOT6V3uiuzWce/3yT9aAN2GQYHFaEDLwCayoSB905+taNqo5LNk0AXRNswq9DT8q2cZLGoEdM8807zsH5TxQBMpwRnmpg/y4xVRZBv+Y1aX5hkUAIDhvXFOUHIOMCmrgH39TUi8DrwaAJA2ByKVSG6dqjY4yD+FKGAHJ60ATo2BjNTo44x1qmjjPzHHtUqPkfJgD3oAt+cEPqfT1p/ml1J5xVDq2SePrU6E46+1AE2C2PQdqTGGIPApEPOM89uaWRhu4PbpQA0nC8dDSKOeelC8/eORTsZxnFADQFzx1pdxHfNOcdSOKiLZ6A5oAcTk5zRxg+tN9s4oOB3oAXtQxOTjrQuFO5jxVeeUc7T0oAe8ij7x/CqsrBs44pHO7k1GVOetACMNwG01aht1jUu3XFQIFRecmkubo4wueKAKN5mWUtnArX0hcadEPr/M1jSuzA7R81bekK39nRbsZ57+5oA801Zv+JreDHSZ/wD0I1CF4JHIPrTtWP8AxNb0j/nu/wD6EahRskHPegCdTtX3psPOSxJyelMJLfLjjvVmNAVCgZOaALunWf2ltoOMetElsYZGVx0PSrFtb3FoyTBT+FX78LdxCaMfMPvCgDOXgcL1qaGLcCdoU+tRoCGAH3u1TiKZUJwSKAGSoozs5x2qJo8nJZee1SSqyHHGSKrN0GcgA0AK6MvKD6VHdkIgU96nt8tONv3R2qvdqXuWJzjtQBXgHzZFK6hQxA5NOJ2EYUVNbQNNIowetAC2sCyKN64Uck+tUr8RyTZiJx0rX1FktofKXlu5rBAJY55HvQBD5e1uDyaeqdc9fU1YjhLPuA496WO2bJYjpQBn3Fp5uP7vtSrYiKIfKMnpW2lm8kZYL8ijJIqB0AcKi5bt7UAZcVq+1hgbvX1oS1CK4X7/AHNax/cgqeZDySO1UfLJY/MeaAMm+0pbuIrISzetcjqnh66gYug3g/pXomwjIA5pWthMmHPFAHj01u0TfMpDDsahnXem04ya9SvtChdS20HI9K5XVPC/kq00L8joKAOJuNkDBUUHHc05bsSgK/AAqS+06e2lLXAJB7gVhzSIZ9iZ6457UAa1n++lYKMYrZtHZON2MVi6btCkAEEHr61r2cJeb5l4PpQBv6crSv8Auic+td/pJxZRozbiK5DTIdqKkYwa6y0j8lFU84FAGrEx71pW0p29evFZMMmQQatxscDB4oA1bZt0hBINWU71lQPsYE9R1rQV84bOc0AWFIUe9WIpdwx0qmpyOORTlJUjtQBc56in78Ac4qBXOCAc/wBKlAxGzjovGTQA4tzz+tDy5A2/nVcZLZzT8AE5oAVH+c8GrSYA44qogGc5yanQZPJoAmJ+bFTqVxyOKronIweKtKqKRk9qAHpn0p7oQDxj3qMN0wOKmZi0POKAI889Mn1oLjg9/amk/wB6k478CgAZuQDzmkdwOopHbgBehqMg8Z6UALvLLjFA4IODmlC4GTxSOcgetADZmLjHP0qHHcrUo46nmg4I4FAEJBBBxTQoZialIPRzgU6MqP8A61AFefgcZ6VTkUHOc/hViY/McnJqFz8g29O9AFOVygABFbujsTp0WTz83/oRrnrtgOh/St7RP+QZDx/e/wDQjQB5fqTf8Ti/AP8Ay3k5/wCBGolyTxUerOTrd8OwuJP/AEI1Ja5Zfp3oAtQq3SrsGBj071Xjz0qzGpVfagDStbmSDBBLp/dPNbNmIJyWjwNw+Za50P8AL6Y96Yty0b7o2IIoA0b+P7JdjAO0nirl2HNm3lj5SM5zVUynULTGR5y1d00tJYtHIp3AbTQBkKVPDH5wKhwOSeQacRsuHGDgZFLLFtjVgTg0ASQTRxxFR94/xY6VXZPmLZz706MBSCwGKsPGhBKdcdBQBSjj3yAnitWHEEXn47YANUQAjDGSTVyWJ5I0VR8qjmgDKu2MzljkEmkitsMpbp2FaaaeXYfNgdyae8Yg3KoDepNAFT7OB90hfanRxDBU/jSAoRkqwbpSAEnrj2oAnMhEDxpxn071AIPKjZsZlbt6VYiT7OvmS4HoPWq17KZWJBxn0oApPHg/MfmphRB9c9alaNj3GKTZ8vSgCPcMgYGP50r9DtFOkjz0H5ClSNmGM496AIogX+Xp61V1WJWhxFjI5q9I4jTavXuazZ2LE4agDkdStjJG/mgEHjGK5K58OLNL5kKkNXp09n9oHyjHvUA04QjgcepFAHm1ppE8M4Ewwo79q3LSJVmG0Z967T7DHNF5ZUZ9SKoT6d9hAeMbv6UAXdHt41xK5INaMlykkxMeGA4rkNX1YWNq2ZFUkZxmtDwfdG70SKcg4dm5PcbjQB1UHYsfwFXVIIAXg1mQNjGBk1fV9uBigCygI6dB1xVuCXaQOxqgjHPv6VcixjHSgC5HJyTntThMA2WqrvYEeWM1LGoiPmT/AHuoT/GgC/BmQbifLj/nVxZI3TbkKg7DvWO9w8xJJ4HQCrVum4HPAAoAc91EsuxlIIPFPkYcEcg96pSoHl3Hr6CrEb/wfwn9KAJo2I9Pep0O7k8AVXgfDFWUE+uK1EWNoicjPpQBFGwACjPPrU5PPfNUyRv4PHpU6N2zzQBZUjA4qUH93g1VU4x1606STPyjgUAOZxnHJI7+lNkJ7k5603mlfO0Ht60AKvz8AYPanPG0eAw60yJiJAfQ9atXJ3uGHIAoAquSo96Zyc7utPcnPPftQF4GRQBGwPel7HimyHHUd6X+HgjNACHGOTx3pgOAcdKU8GkOABuBH9aAK8m0t82cVDOQv3cfhT5Wzn061WkIIOelAFK7YE8HJroNEOdLh/4F/wChGuZn+ZvSum0MAaXAP97/ANCNAHlGpoza5fk42/aJP/QjU0bY4HFR6s3/ABOr7g4+0Sf+hGlicEnA575oAvwjpj6mrPmgAAHmqCSYXGaljxwTwaALYkPcfSno0LOEmyAO61ErZAwB9aHUA5HWgDVtri1tEJiBZu+a2dOuY7yL5FKGuf0yx8475TiMfrV+4uRGqpaZ47igBtxplwty8i/PGTnHerthpjyRsjjCuOM9QaLS/mWImdCTnitizulmXAYAjtQBzFzptxby+Wy5wcA+tTR2xh+8OSMV1U8IuYCAfn7GsePQ7yaQ+ZIqLQBRisVyHJ/EVPJGhKqvB6mt6PTRbWzIv7xsd6zLXTrjzS8iEKPU0AUs7CC/TsKqyxlvm45PWrd1CxlO7PpipEs3aMbiFUUAZJhG47VJJqzBZeUvmyj6CrrSQ2wwmHf1qJbhhKN5HPagDKvHaZ8kYx0qERluo59auXCqsrA8kntUe13X5eBQBVEYBIzk09IdxIHIq5b2jE8qT+FW1s2B6BRQBmNbKg+bJ+lQS4xgcelbbwgDYMNxye9ZUsHOCDQBmTRDODkk1XFvg4P5VpSqAdq/nTFhUA5NAFLymQj09KVlBADVPODswpqCNDj5s4oAlhgRULZrH1u6SC3kU8nHBrVvJvKjxjIAri79rnV9SjsrJGklkbaoHagDktO8J6h4y8Tx2Vs7i3zvuJT0jSvWtUsYNLvFsLVNtvbxIiDGMjaOa7vwh4Rh0HRhaqwNxLhp5B1ZvT6VyfjgLD4lnjHZE5/4CKAM+JSihgeDWhAQz4znisy1YlTux+NXI5djjb260AW8EP8AMfwFSgySuFTJJ44oSEz4cHandqkMqxrst1IXu3c0AWEKWo4bfN+i0hzITISSe9U1xuGQc5rSsNg3s57cCgCNOnOBV6KXBxnrWduy5+tXIsD3xQBKVBbJ6VKq4HHNOYrhSwJ471NbRI8oG75T60AQ5wQ351rhdtoCg+YiqdzbIk6InRuwrTmmSG3CqOSKAM0w44yA/erFvbvI+OoHftVG6L8EYyT3Nben5SFQ3JoAEsM53v8AkKiltJUJYHcB6VpggiloAxATTicjnr9alvlEcueMHnpUJPHGT+FACA54zVm1kAkCucr61DFC0jBcYBq6qRQ7Q3X1oAguCok+TB71ExyQfWrF3Bj5kPHcVSCFTkk0AEozjGc00vt4YfjQ+STzkfWopt23pjNAD2bPXAHrUUjgjABP1qMsVG3Ofem57dqAIHOe/Sq0smwkseO4qW6YIpIrnb+7JJyTx0HrQAmp34QkRnHvXT+F7nzdCtnznO//ANDNeY6ldiTcCcE+9d74HkRvC9kV6fP/AOhtQBxmpgDW79iOBcSH/wAeNOhKnO1evPFRay//ABONQAPH2iTP/fRqGOXKFYieTQBpkRhS0eSw65pqvkiqsMrL93j39auxyo+Ny8+ooAnjJ3dRV23RXlCu2Ae9R2sPmruRAAO5qZMt8sa8dzQBuwOPs7pGMIBjPrVOLKnbGNq9z3p7ER2qRgjnriq7S5Py9BQBfvCQo8rJIFMsIJRKJ2YqB+tOtlkmlUsAFxzVmZ16L0FAG3b3McsIWLgjg+taEG4Q8kk461xSSyRuDExDH0rsdNdntkL/AHsc0AQW19l3jzkg9TVySULAWJHSsnVwYnzCAC/WoWmEVkVlO5yOPagB813CM7kyfWsu6uXkDc4XPAFMEpJAankLjOKAKmGbIAqQwsxyx7U55MYxUUsjFevtQBIvlc7u1OE0aZCqKqqOOtGcfSgC59oO3KjHoKglncg5Yk1C0+5uAB2puMHPUUAN3OSDkgUpnIAVxke9KxBGeKhkcEgUAKypLzGdpHb1qpMrRn5wRSyuoYhetSwTZQpINyngZoApDDnPf0qWfEUBbpgVMCqsQqjGaz9ZvVijEaKC7dB6mgDltbv5blvIt97SMcBV7mvSfhx4U/sOxN7eqG1KcZ+b/lmPSjwP4YNo51HUoFa7b5okI+5nv9a7eBHBZ5T17UAOtkKoWk+8a8r8eOi+KrnOTlU/9BFerHEmGJwg7eteN/EeXHjG5CHqsY/8dFAFK3ZnkwAWz0ArXihEYDTAFv7o/rVSxX7KmG+QEfM57+wqVphI22MbU9zQBeFy0p2H5VHYU4diKpISDkGrCuOSDzQBNuIer1qPMyBxnvWdGCXG/p15q9ZuvmgEkD1FAEqxFXx3q2MHGDyKRmPmkR446n1qz5W5MkjPtQBEMkY60sLFZFJ6g0gSYScD5fWnkF1IIAb3oA0VZXmVz1FOuZF8xSep+6KjsoQsQ35JPalklQkgjLg4WgCC5UBPmwa0tMullCqPvrwazTGxQlmx65qKImOXMRbNAHWrnJp1ULC6aSMbxVzfkUAZmolpJVAOPpU9vEkYBcDpTZ4iZdw6dqz7q6O7y8kAUAastyijC4rPkkLsSTVbcDxyRShiD/SgC2LoqApPHrVa6mZWwp61CxZm9eaUcnJzx2NADo5P4sf0onlL8nAUUxyOgAxjt2qMgt24oAYz9eKgnuPKj55BqVysaEyNwBXO6rfLuJBwooAXUdQIUk49q5O+1EfMztio9V1XexQckVzGpXLtHhm247CgBuq6jliVJ3H3r1b4cOX8Gae3PPmf+jGrxNAmSWyTXtvw5IPg3T8cD95/6MagDj9dcnW9QHQC4k/H5jUMBwBTtcOdc1H/AK+ZP/QjUUPTrQBoQtlQvNWom29MVStz8wq5ENxz2oA27eTbbqZSAp6Be9D3BIwg2p6Cs9C3Gfyq9AjHGBxQBcWQiBUwcmpoI+Mt09TUaIF+aQ/QVIJC3fAHagC+G8uIInLv1I7CmjnvwOtRw9C78ccUhbPAGBQBYt086UrGDxyTXXaey/ZUK+lclboUXOcO/Ax6V0VkTHDGg5GKAHanEZEUxgbs1hXcc6Z81cD1rpkUs3IrP8QsEgRR1JoA54ZLc1djYKnzgYqkpI5709psqVbH1oAlmtiw3RsCPSs93/eY9O1Sm5aE4B4qqJo5HwRhjQA9pCBkfrUJcuScmp/szNyGBFRiNVfbuoABnbnoKfvG046VE7YO0dBSFvl9KAHMc8c4qvI3XBIFKZcgiombIwOlADQQx96cox82e9Iuc8YpwJZlVQWY9FHegBbhxGisASTwF9TW14X8MyLdLqOooGm6pG3IQep96v6BoIQC4vMNMeVTsldNlYYy0jBQOpNACou0lnxn1qO5mVRtzz6Cm+cJ4t8f3f4feswStBI3nhiT6CgC48jNHyBkfw14v43IuPFd0Y2DABVyD3CjNdL8TviPbeGtPktbHD6rKuB/0zHqfevMvCE02o6aLm5dnnkdmZj3+Y0AdNZpIyDzGZgOxNaKBT8pBz7VXsioO0g1eCgOT0oAiKtG/wAtW7RVByev6U0gMM9eKIyEPA/OgC44LMWyMVZtvLXGeTVHdk5NTISTxQBqNOf4cKKdFctGR82QagT/AFYwORQoLv0yfSgDVt71XJVsLVmEecWII+tZcVrI/TAzW1pkLRLtbDNQBKE8uLOdqiqYmhjkYjlj6CtK9iMsewVlJYsGO88CgB0kyyDDDJ7D1qa0hOd7jA7CnpbIhDd6tqvy84x6UAKmVx0q9HhY8k+9ZM8nloTnkVGl67IU3delAFu6lVmwpPWs64A3EMM570DIJZjTJJNwIH60AMX5MkE0qvzk/kKbu4IIoIPHpQBLnCluhPaoyTnk5GKXluvAp3yqOcUAJgYz2qC5mEakmmXFyEzg81iX92zDJbA9M0AJqF8z52g8dK5nUpS2RK+DVi7vsHAPNYepXBKnHpQBk3jYc44A61k3Hzk9MVbuHxuLmsyaYBiB3oAhckEqDxXtnw3/AORL07j/AJ6f+jGrwyeQLXt/wzcN4I00j/pp/wCjXoA5DW8nXdR9Bcyf+hGooDx04qbWx/xPNR5/5eZP/QjUaH5Tx9KALMTDI25rRhGMZ6VSs0Z14THua1YRHFgn529BQBPawtIwwML3NahdYECRjJ7mqccxAG4jPYelOUkmgCwmZDk8VbiSMAs54HYVTDc4GPc1IG4wp4oAsvK0nbC1NHtjX5+WPQVRRsjvmrVupaRQPvGgC1bEgGR+3ArpNKJa3Qt1xxXOXH3o4EONx5xXVWkQjhQDsBQBaGNue4rB8SNl4gelborldeug96UHKoKAM9nHIFV5HwM56U/cnJ6E1UZtzY52igAEpc4OTT1hVW3k/hVW4ukgTCAE1Vgvt8m124agDYWbaPkfFHmI4w/B9awZLg+awzjFXbaQyqec4oAtTKVG7BI7EVGrZ5yafDKY+HXcp7Gn+XGxJQnHp6UAQEE5xT44xg571YWMBeTirum6ZLfviMFYx1c9KAMyG3luZvJt0LOfTtXYeHNHjs0MkqbrnoWPb6Vc0uxTTImBClicbgOTWjuAXe2ABzQAw7LdGdzgdzVSRF1NBuJ8gHoO9PcrfgoM+WO/rUDzi2mSGMbU/T60AMklkt5tu3KdFUVxPxP+IUOg2r2mn7H1NlwT18v/AOvSfEDx5FYh7LSGSS6Aw03936V4Zdq91dPPcM0krnJLHqaAMWdZ9TvXu753kdzuYseTXoHhH93piYGFycD8a5KaP5c4xj0rr/CaFtLiDZAy386AN63djLkH6mtlWDxgkf8A16yI0GNq1o2p3AITzQBOp2/SnZ9KrzHa5BqZDlc4oAniIIAYfjVlXAJ29feqW4AHripE6ZoAvQuykYzzWvYwKqFiOT3rFt9578eta9rfBI/Lb6ZoAnW9VHwM8cVqWk/y7znkdKx/IV3VwMLUs0zyP5UPCgcmgDdtZ1uBvHQcVYlhDJnGDisjTf3Cbc5Gc81fkvAqYzz6UASwW687j0qdjEowSPfFY4unJwDgD0pJbgFSCOcdaALFyiTNgkYHaofsgLZVulUDMQ2VY4HU077ZIvQ8GgC/PErRnA+YdKp+Xt+9xTBeN07GmM7Mck5oAe2O1IzKoG5sioJJwgIqjLLuzjOKAL0t4FOAKrS3LtnnA9KoyThAM9ap3N5sU460ATaleBVIXrXPXF2GYg1LcTFs5PXrWRczqhOT060ARXMpOcYHfNZN9cHkk+1Ov7wv2Cj2rFuLjkluc0AR3dwzEqOKz2J/GpWO45zTcgNz+VAEUiZ5IzXuHwz/AORI03Ax/rf/AEa9eG3dyqR9K9y+GCyt4F0xjGwyJD07eY1AHL6qjNr+o5U4+0yf+hGpY0ghAYjcx7VF4gunOtX6LgKLiQcf7xqpbEuwAyc0AbDTySKFjAGew7VNCvlgnqTVS3PlgKOp6mrSnnpxQBcgO7BP61aQluQMDpmq0GGI96nkmVThRwKAJg3Yfdp6HcT2+tVY3LY4/Kr1rC0hG7hfU0ASRDPCjJq8jC2TBOZD19qr+fHCCsPLetQls5Lck0AWrWQy6jFkjJNdxG2EH0rhNJw2owg4znNdzHjb/SgCXdlTiuI1QMl7NnruzXbJn0rj/FYWG/8AQstAGRISxwDxUVyWWDEf3j1pFlUDjrSli3UcUAc9dmf0qrA7JcAHJYV0F1BvGRVSCzQThgOc96AKsbmaR94KuD371s6WgCNUWoWZ4aIc9/eks7jySA2PQ5oA1NgyOtKvyvgZz6CprSJ72QLbDeT37Cut0jRIrXMk2JJf73YUAZ2maC1w4luziLsnc/WuihijsotsQwn8qmd1ijyOlV1WS4b5/lj/AJ0ASL++bP8AD60XCeapjH3e9Sldse1OMelY2o69a6ajteZjhUcE9WNACyapa2svkhljhQfPITgCvLvHvxAju3ay0Q4jGVafu30rI8c+KZvEFwYrVfs9qOAo4LfWuQWyKA5596AGrl2JYliTkkmmzpswVA/GpDEU4XilaJpEwvXvmgDPJXLFiMDk11nheQPpaFTgFm6fWuOulOTGRx611fhZNmkxheAGb+dAHSxDA5qaKTZKCuc1Thz68VPkcEnHagC5MA7lgadGScKQcVTSVTIRk1ct3UHAoAsRp5jbQKsRIc8j86rK6rznmrVqwclmB49aAL0Nqz4+YL6AUC2k80DkjrkVXhlYyllPC9s1r2l0mPm79aAJl37VUcL3qaHaoJPFVTdowYLliKr+c7cAfLQBfnu1XhOtNSU4znNZwJ3Z7VMjjGRQBoJKVcHjnrU0koaMqvWs9HzjFSbsUAQ7yz7R0FO3dj0pHTjKimlgCCeSKAJUG0Uy4mCDC1HcXCxx57noKyp7rLHNAFieUnknAqhNdnkDoO9V7i635UZOKqGTGc9DQBYefnczZrNu7sEdQKr6hfBAVU9O9c/PcMcmgDXuL0IcA/jWbfTeYcr931qgbkAZY/N6VWu7gmPANADLydegPHesouWk9vWpJDgHPWoFJUggdDQBckMQwGHbtWfcXCpnaMU+9u025JAxXS/DnwdJ4kvBd3p8rTo2zg9ZD6D2oAf8PfA8/iOb7fqQZNNQ8DoZD/hX0RolvFa6XBBCqrHGCqgdgCa5HUJzo9uttYR7j90Rr/CK6bw+HOkW5kY7zuJ/76NAHiOutjX9S75upR/4+aWBjGvB5NJrXGv6mev+lS/+hmmR54JoA0oXwRzWhCN1ZVsGcgAVfEq52KST3NAF9JMHC8mpQh25Y8ntVaE4XjCgU4zgH5T+NAGjAyx9PvelWZpdkWwn5m5OO1ZtnMNrPjoP1pktysXzSHLUAX0dY+WI6cVFLdlgdgG31rOExuB1xV+2jVYiH+tAD9EuCmrxbzwTjNelWzZQYryO+uVtWWVThlORXaeH/FNpcwKHkUSgcgmgDsYQT35FcT43mje/RQ6govzEmtHWfE8dlYyPCN74woXua8o1K28QaxcyXBtpAGOQCcUAdALq3iHEgYnsDTHv2VflFcJqEOqaYhee1lCr1Ycis2Pxe0IxJnA4xQB6QNQc8EfhUkV9Cp/en5vQ9q86j8TeY24Z59619Ag1DxDcmOwjkbH3pD91fxoA9AFwskW8EH0xUejeHbrVb8/aXMEGc4x8xFdH4M8OLpiM+oYkcdGbp+ArqyBkm3VUz1fFAFfT9MttNiWOAEADGO5+tXpH2jP/AI6KqXFyIhsiy0nr3otUkJ3E5Y0AWolL8v07CpmGF47VG8iQRlpWVVHUnpXEeJ/F0hVrfSTjs0p/pQBreI/Fdvoiss2JLgj5Y1P868k8Q6xd65dGW6f5f4VHRaS5tnupzNNMzOepbnNQTwbYwOvqBQBltGMkL+Jp6KMMD2pSu0kAd6UAhuB8nc0AULhCCx7VXJcDavBJ5rQc5ycVVVP3mT1zQBSngLsSOfWt7Qj5enpx3PH41GkSH7vBq1aoscO33yKANFbjAyQB7U4ylhkDr2qtCmT1ye9TDAb2oAlTJPvVy2c4wCPrVNOT04qaNwCQBzQBqRgkDP8A+urTkJGE796p2pY/MwwMVIHLOQBzQBMhYMSnLGtWNHFvuYY4qnZx7W3kcitHh49rSYzQBVUk55xUkDfvMgn3qvyAVUkkHrT96oCAfm70ATM+GJpQ54xzVUNuz2qZCFxzzQBbifsB71MHI+8cCqSSiPoQTQ0oZeaALvmgIVB/H0qhcS7Blj+FMaf3xVC8vEcEh8leooAbcXLSMSTk+lUpJs9+aq3FyoBYHArPkvlJwOfSgDRZ2/DvVDUb4QKVGdxFVp78rG3PJ6Vz1zO8khJY4oAnuLlnYnJxVOa5P3VGTRGZWzx8vfNVZ5gjckCgCdQ+cuuB1qvPIDkKaga+JzkkjpxVZmMisy5AFAEsxAPzMOarSzDawTg+pqhc3RU7RktXonw78B3F3JFqmuRFbb70MB6ufU+1AFP4e+CjrF2l7raPHp6tlUxzKf8ACvXNTFrpUSrpsSo+AqqnRRUuoahHaxpCqKJwNqxqOFFQWFkYi1zcMS7clSelABYxSInnXpDORnd6V1+jMDpsJVeOcfmaw9OtJb6fMilYB0U119raxxW6IoGBQB8662R/wkWpZ/5+Zf8A0M0kDDseD603xAy/8JBqWDk/aZf/AEM1RFwUPpQBt+cIotu7k9aatwoOc4rFExkJJNTxnLcnigDbF4zNnoo7Uv2hi3oKz4iD3qfcd1AGstz5dmTjjPFYd5eNJLyxxVu7nAtFUEVihwJzvP0zQB0ukgkc4x9a6SCC4mhxbW8s2R/yzQtWD4bsL3U2Mdhbs6j70h4RPq3Su58Ja/pGlXUmiy6wlzcANMzquIYiBkoHPXjJ9OD0NAHJXngnxDqjmWZYLG1Qbi1zKBhR1Py5x+OK4e7EcWqfZ9OvDdLuCCVUKBj7DOce5x9K6T4k/EN9clk07SpHi0tDtc9GnPv6L6D8/QcDbXn2K+guH6IwagD3jw/o8VlpsSXDebNjLFucGpL68ZHKRDAHHFZuha7Df2yujg5HrV+SRC2Qm49gOpNAFW6WOaydJV+9wQRXlfjvwvHcqn9l25a5JwQg617PZ6BdX7hrg+TCecd66S20mx06NTDEu8fxkZJoA8I8CfCXUCY7rxGpii6rCD1/3jXtGjQafpVt9l02GPcvBCjAzUup3jSBomOAR90d64bVfE0WiXaQLmSSQ4VFGefegDtbm5jtnM19MNo/h7CiHUZL87bVSsfZq5230O715orzUmeGMHIjz1FdaZ9O0Ww33M0UMaj+IjJoAt2tooQFuX67qpaprdrpIdWBZx0C9zWE/isXyuunvhCcBj1IrLdS7M0nzE9SaAIdZ1i61QkyFkjPRF6CsTyWUkkHPvXRx2ybc4+lRzW6EdKAObcYbGBVe7TaqsBW7PZ5BKgVk6hEQMPwR0FAGPMQeqCqFy5BCgcCtBim75jiqc6qTxQBEEBUA8e1RyqA2BxTycDa3HvTcbmznp60ANBYP8oxVmMkDk1CUO7OTg1IBlyM4oAuCXbFnuaVGH41EkEjYIxjtVy3gSPm5YY7AUAS2qs5Cjhe5q5uWLhRlhVc3kajbEABSJcM2Noz/WgDRimkdsAcVoW4RfmcVl27FRukOParQm3ccKtAGmLvaPkAx6UNMjNu6N6Vnqe4p+7A6c0AWJZicqrUxG6k1AGNBcAZJoAtLIByOlMurvbFlCBWfcXYQbVPHU1z+t6mY12q3WgDbfVdgyW5p0OreaMDPvXGQXLTfMxwAamjvCzERtgd6AOoutVxGVXtWTY3W6/y5OD6nrWdPersxnn1qg14YbiNvfmgDtb20SdPl+6fTtWHcWM0Ddyo6Gt/SrhHjUtkhutN1VywZI+YyPvAUAcbdzKj4kcVly3SISVBYUmvRtbTsBkg85rIWRsfWgC/PqMrKQvyr0wKy5Jt0gycc0kjYXk/hVSSTLDtQBbaVQTVaaeRisUIJZjgAdSaZCJrq4WC2RpJXOFRRkmvZfA/gODRrdNQ1MLPqrYZIjysf/16AM3wD4BFrJbal4hQ+c/zQ2xGfoWr0bWLySxXNuvmztgBVHC/Slv5mmj8u2w12w/BaNGtZLYBLk+dcnq/pQAWVmjKLm6w10RnHpWtpumzTS+Zcf6sdF9KtWOlATeacluvtVLxd4x0/wAN2bqXEl0RhIgeSfegC54n1/TfDmjvNcygPjCovVjWN4M8RXOqeHLW8YkGVpOD2AkYD9BXhfiPWLnW7p57uQnJyFzwv0r1n4YgDwPpoA/56/8Ao16APMPEd5GviXVVDfN9rl/9DNU/tPmdGBrn/F92V8W60ueft04/8iNVazvWVhyfpQB2EDdPTvmr0ThmxmsexulkQFsA1aN1HGcjk0AbcRGMA1BeXDIwUHAqtbXoYgY603Upd4+QUAV9R1PZCFQksD1rLN474Zs7jV9IEliO4DdVaW1ONyjgUAbcfibUpNGt9Olu5PsMGQsS4UHJJ5x1696lgb7UG2gA7SSa5+NCsR38AVNbalHEXRSemBQBVVVWVmc9Cc1hX9+k166+YBEg6etWL27cq8EClpnOAF5NaeieBp9L1OzudeWNvPIdbdz69M0AdT8J9E8Q6rco8VvJDphGfPk4H4DvX0Bpukw6eqj/AFsg6u3rWXoUktppUGfKgiVQAiDA+lbiXQkjDoM5oAsPIFXI/GhiJUIqvE25ih5J54qzbwMCC/5UAYl/Y3N58lsNrA/fPTFJY+G9LsGa7uVjknX5mkk6Iau674i07Q4SbmUF/wCGNOWNeI+P/Euqa4sqWkr21o2SY0PJoA6Px78ZrDSfMstDRbu8U7fNP+rX6eteNah4l1HWro3F9cvI7HO3PC/QVyeqWD2R8yV2+c9G65qOxuGDgDOelAHrHhjWZLaRDvJ9QT1r1Kzu4rqFJIznI5HpXiWiMghUkZOK7bw/qTI4UN8ooA9Fi9TSsqtx0qrY3kc8fB+YdqsBufegCpIChJ6gVlauu6IOFG8VuzYwDjg1iaknzHrjtQByd0mW3Y+tVmXd3rWuouvH1ql9nZiSFwKAMefeH2k0sbMcKfyrUe1DYLDmmLahWyBQBHEpKnIxTZZlikOQNwFaKwjAGAM1j6rGI9Qdc9AP5UATJcSEfeIz6VIm5z1LGq1vz0q0riI/u+p70AW4IQozM2B6Zq7FMiD5UrMiVpXBYnFXPNhgX52AoAvI+4k9qljYZGTx71gzazGhxGBgdzVGXWJDklsDtigDrp7+KAcsC3pVCTVyGwgFcv8Abi+SxJJp63APJPNAHQjU3duvX0qeW+2RZ7n1rAtjnBBo1S4McWQeelABqWoFcvvwewrnpbqW5kIc/LVa4meUhSSeaWKRQcdMUAaglAjVV4H86nijIgaTtWZFuds/witRZR9mYNwOlAFFN8k2F+7nn2qa4iJCxxgvITgADJNeneEPhkt5aQXuo36G3mUSLHanJYHplj0+gBpfiDf6R4Us30bw/bpDfzR4nuEG6SNSPu7jzk/oD70AeWaP4gaK4NrIfYNXZ2mrE2TWjFPKc53Y5B+teRXKNDMXLYbOc1t6JrX2giJm+ZeDQB0mr2wkjZHAJPQ1wGoNJaSsjevBr0A3KTQmJz+8A+U+tcn4gthPG2RiReRQBzcl5k8k1LpFnea3qMdnpsLSzue3QD1NQ+H9C1LxHrC2GnRMWJ+dyPlQepNfQvgzw1pnhWzMFn++1FxiSc9T7D2oAj8EeD7fwra+YyR3OrSD5pDzs9hXS+aeYl5nP3j/AHabAjWny7zLMxzz/DWlaaeD++k+XPJPrQBWsNOMLfus88s56mujs7NWUEdv4qLO3Mi54WEeveuF+IPxBTR1l07SWR7jGC452UAaPjnx3baBC9paDzb4jAAPC+5rwfUr241O9kubyQvKxzmop7ua8uHmuJGkmc5ZietKiYPAoAQqPLwBzXtvw1t3XwTpo4/5aH85GrxNyR1r234buT4L045P/LT/ANGNQB8yeNLpE8Y66M5YX8//AKMaqMF9yDniovG+P+E28QZP/MQuP/RrVmW43HCtyaAOutdVPEan8a2opGZATzmuT0u2LSjnJrtbe0IjQE84oAt2bnjAwauSo56jml060O8Z6e9bMcClwMDNAGLbxSFx8pwKvC3BYbRwetajwKi8OMdajtpoQxDOPwoA53WYikBY/KorzXVdeZb0Q2o74LV6l4wIkgWOFsBu3rXO+BvA4u5dS1bUYx9ntRmNSeGagDsvhFZaR9mmu7+3kur8DcB/d9hWz4z002ca+KtYkeSODmC2HUHsDWD8OtUa2ur/AFW7iS30y3yox0JFdJo8Fz4w1ttQmkY6Zn5YG6fWgCTwLrWo+KRHqV4rwW68LB0Fev6UomiwBhcdaytE021t4/KhiRYx1AGK5Lx18UtO8HvNa2IF5egYWJT8sZ9zQB6XeXVjpEHnXk8UCdN0jYzXBeIPiPFLvt9E+YdDMf6V8peMPGWv+KdUe41i9kZCxKRKcIn0Fdd8MdRa5DWsz7inI9cUAeiXDPdyNJcOzyMc5J5NUnTBxWoI4lYEnI+tSqIG6hc0AeaeJ9K88Sl42IHIY1xNih+1FQp+U4zXs3i6yM1oqxttjYdRXnNvax2dyR5gkIPPFAGppZaK3G4Hmt/SZmWXIBx3rFEyDGD2qa21DDd+KAPRdFvWWUFc+4rroJfMQHvXkFnqzRSA9s13ugaqLhFNAHSMGOAQcVVvrZioZRmplmJPBokd3XgZxQBzs1o5ydp60n2OX+7itbD7yCvFKNxP3aAMF7GQZO3PpUQsZi3KkV0iMCcFelOUEnlSKAMiHTTgZHNcn4ki8jWpUb0X+Qr0yFQeADXnPjUbPEdwXbChUP8A46KAM6Nm6DgUTX8UOFLAt6Vz+q68sCGOFufXvWKl07ZeRzuPY0AdjPrRAxGQorPm1NnPLfnXNtd4/iqM3WeAeaAOhN4CNxIA71C9+jNwa5u4vGPyqeB1qNbk54/GgDrItRjz9KdHqYZsKtcwkpJBq9aOC/JFAHTxangjPAqlqus4JVRuzxVKaZVHyt061lXTkZZup6CgDQl1EKAAv1xVi1uIZHG47fXNc4ZTyG4qjc3+Pk3/AJUAejQzQK4SJwx7122leG4G02PVfEczWGlfeRR/rbn2Qeh9f/1jwK319rJ+CW+tbh8YTX0cKT3MkgiXZGruTsHoPQUAe72nxOXS7a5tdP02G3sUi2WUanJjbP3nPfOST7j3Jry7UdVmmnlmnlMssrFndjksT1Nc1/arP34pst6j9TzQBavmjn+bvWO0j2sokjIDA/nSXV5sOVPFZzTzX1wkFnG807nCogyTQB1+n6wkyhnf5x1Fdj4b0G58WOuz91bpw8zDgj2965vwR8Lden1lpNdiNlYRAM+Ty/sK94tVt7WwisrGAQwx8DFAEVjptr4diSx0e3UFl+aTHzOfUmpIl+zXWyNfMupPvN2StJIGlULbHMp+8x7VowW0NmmEXzLhuw6k+9AENjp6WyebOdznnnqTWpGiCPz7wiKEfwn+ZqOV4tOtWvtTkVQozyeFrxf4h/EObXJGs9OYw2S8Ejq9AGz8SviGHd7DQJCqLlXlHf6V5MWeVi7sWJ5JPemKck571MpG3AoAlhjAGT0qyo4wKgjBK+9XYFzgdqAK8kWSc9a9p+HKBfBmnDH/AD0/9GNXkwg5z2r2PwCoHhKwGP8Anp/6MagD4v8AHUkn/CeeIgGOP7Suf/RrVX08TMyjFb3iux3eOvELN31K4/8ARrVe0qxgRwX6UAXtFj2KGI+auusZcgbgDWYkMSxjyhTrefbLgmgDooLvax+UYq6l2IkMj9T0rmmvEjIyeKL69Mtrlfu0AaGoawMMoOPfNcs/iWO3usNIDz61zGtajI8xjRyFHXmueuJCquxOTQB6NrviIyLGYypzwMGvbdCisl8FWekkK1zdKGkAPPNfItlfM15BExzucAfXNfSvgLRtTstYtJLss58veu7oBjgUAaXjTwetzbafomkXSQx7w00Xdq9F8P6ZBoNjZWVuFeQYDH1rC8OWV1P4jubu+VAeQoznFdFazQXurSW+1i8Ckhl6cCgDhPjF41ttAuJrTTpHOoMnzbDxHXzdeXUt7M8k0hMjnJY9STWp481Ge58TalJctl3nYdegBwK5t5hxigB9xDuTqcjvVjwheNpfiO3kdm2P8pxVeOQudpHWpxaujxXEfLIwOKAPbIb0SYwxqxFOcg9qwdLJe1imYcuoNa1qrOw+tAGjqc5/sxu4rzDWHSK+cxEDPJFehaw1wYFjtVBJ+9Xl+qWtwupymYHk4FAF9JmZVIParsa/J71n2yHACjkVsRQNtUhSaAEgznB612XhyfynjXPBrmbaAu4OOa6DT1/fxKo6GgD0a3kzGvTpV2EjIxWbEpCJ7CrcZ6HPNAFl1UnJAqPYmc9KATjnqaaT81ADhGuegokljTIbFQ3M3lpwOax7id3b5evegDY+3BfuAYrxn4raoR4juVDfwJ/6CK9JV2C5Jx9a8U+KTlvGF0M8BI//AEAUAc8sxkk8x+TSvcnd14qg84QHNR+d6/hQBcabJoM5VOvPaqP2gFsfnVaa6JY46dKAL4mx0NSxucbqyYnyc1Lc3Xlx7c4PegC6+oYOxePcVZtLk7gd3HrXNpMGbg5rasDuKgDmgDZWZnySflWqN/qPlnJPSpr1/LhxH93vXE6telrplJwBQBr3WtRyZUN85qmZgAGJyxrlJZCtwzg/SpIrqQ9ZDkUAdA06k5Y81XknOcocelZAu3LgHpmrkcnQ9aAN7TtWYERydh1rUa6LLlTXGyNt+cH5s8VdtL6R3jihVpJJDtCKMkmgDSvr1lOASW6Yr3b9nbwhcaf5/ibWbcoSu21Rxzz/ABYqp8L/AIUrbLFrfieLzJyN8Nmf4fdq9ekWeR4lhzGAMBDwqj2FAEmo3E13amWQOiliFXu1P0ewunQefhUPUnsK1YIAAjXHzsowPQVejtZrrgHYg6n1FAEdtiIi3slyR1f0qS/vLHw9aPdXkqhsZJJ5Y+1YfjPxxo/g21EMzI144+SEH5j7mvHX8ZXuq6lczX6RzQzjaqt0jHtQBH8Q/GGp69e+VuZLAH5EHGfrXMxLtA3DmtvUYBImEXpyDWSsTFhnpQAEFj0wKkRKmWE96niix0FADFUhav2i561XCOeAOtXbWBh8zcCgCcZzgZIr1/wMhHhayH+//wChtXk6OEPy8561634IcnwxZE/7f/obUAfHnjbUIofG+vgvyNQuOP8Ato1UYNcjXGATWL8QGb/hP/EnX/kJ3P8A6NasdZmReSaAPQ38XpAgQAk1NpPiKO7mw3BPrXmwczAAnnPWrumiWC4V+woA9LvbwpKCTx2qzbXxmhKr0riZtQknAA7Va07Uig2OcHPWgCXxFaeTcCdfuN19qxrgLNCzIe3SuqldbuHy35U96wLnTJrWYsqkxGgDA00Z16wRuhnTP519lx+IYLLXYVYhoBZKVHckCvjl4THqttInGJVP05r6DjvYR4j0+O8cF3hVAvtjrQB33hLxQmoHUJ44dpHPJ61S8H6zd3Hiy8hiYxyMGbYf4lxzV3wD4agtvtYecZZzhB6Gunh0qz0rxDbX0VvGr7TFJJ3OaAPkTxrPHdeIL2SIEfv3BHvk1ioCG3Z5969J+KHgy68P+JdQnkjBtbiVpIZB90hjnr61541pKJNwUketAFi3YHAUAHua3rBU+zsoOSawdhRduOT1Naulkq6jGTQB7R8PrOLVNFRWQB4vlNdG2jiHcQuBXH/Cm7aDWFgP+rlXke9etzWrTfLj5aAOFkspBKSo4rzfxjA632XXDA179baSNwVxkE1x/wAR/DUAgNyoG9WGaAPJ9OgyR1JPNdLaJJInlqAoHtTbG0RHBVc1twQ5HAoAqxWoj4xknrWvo1nvukIHA5qe009pSOML3roNOs1hyVXgfrQBcRTj8KmjHy8UhXIAqVF+U9qAEOc09F3Ng0AYbHrU0SjIzQBl6qwVCc1z7SuZDgceta/iBvLlIPSuelmOcJwPWgC1I4AG414t8TpAPFt0e+yP/wBBFesuGYglq8Z+JxZfFVyP9iP/ANBFAHJzTZJz0qubg/w80kpzwDjmos7RnsKAJZJ8ADPJqFpQXxnjvVV5N7E5+tODAEDqaANGBwBuPQc1n39wWkJBqSabbb4BNZFzP1x370AW4rgqwyea6bSpxGAXPzMPyrjrEbpNznKjitqGcmgDprm5XyGI5NcBqjMLiRtuQTwa6hZg1uVwTmuf1AqyPGFye9AGIxLHJoFGOcVJGoPWgB8MeevSrKHaDg8CoiyxrgEUWNtd6neRWdlE81xK21EQZJNAE0SzXtxHa2cbyzyHaqIMkmvp74K/CVNBjh1bXIkn1ZhuSNuVgH+Na3wV+EEHhW0i1LVkWXV5F3HcMiEeg969Oug6Db9yPP3R1agCF2Xe8cAMlx3b+EVesLIrjzm82c+nQVYsLIBQ+Ain161fhClWMZEUaHLyNxmgAgtcYMnJ9PSvO/iv8UrPwzbTafo0i3Gqldvy8rEfeub+LfxcFus+j+Fpd0nKzXI6D2FfPjvNPK8szs8jnLMxySaAINV1O/1XUpb3ULh5rl2yWY9PpWxpGtNFhJTx61mTWw2bu9QwxfMKAPW/D16l9ZvGSCwHymmRRkyMMjg1y3huZ4Ajxk5z0rvjZ+ZBHdRjiT7w9DQBQaIqKdChYgVaK4znqKjRGzxQBeihQLnvikOc4p0RbZ9RTxFx60AQHK8ivXPAbE+FLHJ/v/8Aoxq8qWByDnpXq/gVAPC1kP8Af/8AQ2oA+GvHroPH/iXP/QTuf/RrVgO6nOOK1/iC2PH/AIl/7Cdz/wCjWrDWJnGRQBZUqiBj+Aqzaz5PLYrNYEYDZ4p27A60AbcM4V87qtPtmXMbAGubWQDqeas29wwIweKAOt0i7kjcRucp7118GyaDY2GUjrXm8N15eDnNbekayhYIz4+tAFrWNAl3GS3U8HIr2XTLiw1bwTp10LVRq1rhHk/iIFcFp9z5qAOdykcGuj8L2wfVoYBLsimbaeeKAPWrXUUtNOtLuNAC4Cue9dBOk99YKqcbhkuOorirTRpxq82mMzvZ4BV+wNdvpv7qA6e0pAVcB+9AHIa/BHqmk3PhvUUeaAKTFckZIf6147q/hG80K3ht7yFwHGRIRwwr6Xkhih8uJoABn75H3q073TrPVrD7LqUKzQkYUY5X6UAfHR0Vj/qst61asNP8iUNJxg17l4m+Gk2lxtc6SDcW3Uj+ID6V5rq1i65IQgg8igDS8ChF8S2mTgMcV9AqkNtbh5CFj7k180abO1neQzJ96Ng1en+IPGSXmkwQwsQSmW+tAHdw6/pguiisGI4qp48t7a78PNNCcs7DivIdPuH+072kIJ5r0Czae/0URglkDdTQByVvpjBxgcVuWOmMegrYtdLEY+dsn0rRjVUG1FwPWgClbWfljBGKsOoUAKOlTe3WkK8GgCMDOO1SgYx6U1UqdF6UANVeQasQx5dSRxSBcH2qeIcjFAFXxLokb6Qb5XJkB5HavPnhIlA7V69Kvn6DcQMuWxwK87ubBw7DbigDKjg8zJB4FeJ/FZAniy6Uf3I//QBXvsdpIGxjivCfi9H5fjW9DZyEi4/4AKAOA2HGaguvkjGT14q8wGMjPXpVK7ZS4BzkUAZ+3a3PekJIfPUVM4Az1pgTJoAS7YLABkZrGI3vgHK1vzRq9uR3FZRRUP8AtGgCSHagAUcdKuwkg89BWfECvckn1q9CcnBNAFwT+VAzHn0rnyzGYtuI3HvWlcybw2Pujisy3BNwM/dFAGk2nrNCGxiTH51n3MYg+Vhz2rbSUhTzxVW10+41vV7fTrBC88zBR7e9ADPCnhvU/FWsRafpMDSzOeTjhB6k19ifCb4UaT4IgSecJc6wy/NMwzt9l9Kn+FXguw8E6PDbQKr30qhppsck+ldjrc01taGa2hM0o4IHXHrQBryOQAFGfakS0Uv5rjc46Z7VV8PNc3Vkkl1GUY9FPWtXUr+z0TTnvdUlWKFBn5jyfYUARSeVDbvc3syw20YyzMcACvn74sfFSfVzJpXh9zBpyna8o4aT/wCtVX4l+PrzxVcPb2jPb6Wpwsa8F/c15o9u+75h8vagCjgk5PQ9fepFUY6Vc+yvt4HWoTEwYDrQAscYY4IppsyJRtHBq5b28rcgVpWlo7yqCp4NAGj4Y0iSVQduQD6V6Jo9k3lPbOCFYcH0NJ4RsxHZ8x4Jro1gYOrAEYNAHKz6Y4dlIORxUJtDH1Xj1ruL+3BCy4+8OfrWNcKCpG0UAYkcRBxj6VYit24zVmEgZUr8w6VpWttvAYrgUAZ32cbCWHNekeD0C+HbQAYHz/8AobVy/wBlj2YK8123huJU0W3UDAG7/wBCNAH57/EIf8V94lJ/6Cdz/wCjWrHt7gRggjNa/wAQ/wDkf/E3/YTuf/RrVz9AE00pfmos0qDJ56U91XqtAEdODkdKZS0ATpcOo60sUrBwwPNV6VDg0Ad34d1h/LVCTxXe6Res4V0bDKcg15Do822Rea7nR7kxuvJxQB9J+CvFcGr2sVhfkR3SD5ZB/FXdLbK1uOAJuoNfNGm3bQyxyqSrKQQRXuejeJ4dR0u1dZALhQFde+aAOla6SSJILhNzZ4Na+l2UigSM2V7A1lW0Y1AxlcI68mujiMkcQjA5xigCzGSyncOOlcn4k8D2Gql5YEWGduvHBrrY8bQO4p1AHzRr/hWfRr14bpQMHII6EVm3lg0JVk+ZMZr3j4haG+p2sc0C5kjByPUVxvhrw22rQTpcL5TRdAepoA4rw5p73t0ABhF+8a9O0+WNbdbaBQETvWeljHaobazTABwzetaVhB5SADHvQA9x83FAB5PepyoxnrTduOcUAIiccigpkYNSR8kin7RjA60AQbe1SKnNO2HdUyKdue9ADVQmrcSquOcn0qmXJICcf1qzaZMg46UAXi5UBayb+zDSbwOGrTcZIODyaRCCMEZGcGgDmLq3eLIWvmz4zBv+E6vCf+ecQ/8AHBX1rNApyHUEV8w/HKzVfH17sGVMcX/oAoA8rLYGSeBVGQlnJzite6gULgcHvVJ4eoFAFMqxIHY010I9+9XCm3BxzQkZc5b7ooAbZQebksOO1Z9/bGNzkcVso+xgB0pLuD7QhPf0oA5uMYPJ5qZiVTPTNSvZvG+dtQzru4A4FADHcrF1yTTLRDuz60pQ8ZGRUiHYRkUAW3XEf1ruPgHpLX3im5n37GhXhvSuIaTdH0ya9M+B8d2YNSGnxM905AQjt9aAPpTSphP5ex8iM7frXT2tmz3Bldj0xt7VxfhuOezjghvUWOcNliOhNeiacQzAZFAEes6nY+HNLk1DUJAkca8DuT6Cvl/x340vfF+rNI7slirfuYQeAPeus+Peo3V14oNi8rC0hQbUzxn1rzPT41M3XgUAX7OzLqGcDPpVtLAScFRir9vGAqlRxjmtG2gVVywoAyoNKCKQyg+lZ19oGJBInQ9RXY4yAAOKswwKVyVBBFAHIafpm5lTFdXpGiRm5UsowKntIkjuMKox9K6fSVQPnaKALFrZeWmEAAq2F2Da2Ca0bWNXXoDU72IbBAxQBSitBc2xQ9uRVOTRtwycY9a6KwtwjlT3FPaEruz27UAcmuiBZgxXir8dsFUfLgCtiTaUIxTBGGUD2oAzDGvda6nRABpkOB/e/wDQjWJ9nJPtXQ6Um2wiH1/maAPzl+If/I/+Jv8AsJ3P/o1qwQvHNdH8Qh/xX3iXsP7Tuf8A0a1c6X4IFACE44FJmkooAKKKKAClHWgDNGKANLTP9cuK7rTVOFI6VxGi83Cg9K7mxYqAATigDsLBS1upPat/Q76TTr2KZeQpGV9awtC3SwY7it63iwQCKAPoPwbrOn6vbxtGfKuMcqT1rr1HIDDJ9a+cvD169peINxVM9QeleuaR4laNFE582I4G7uKAO0AA6CioreeO4jEkLhlPpUtAAQCCD0NYeoaQ5bdYN5ZP3gOM1uUUAczJoEcFhJI7nzVBY46VzwfI4JAr0G7jMttLGvVlIFcM9hNC5WQYIPNAD4gNnfFP2ZIODU8KfueRQByc0ARhNpqTZxUioD1FOlAjXdQBEE70ruqRHuxqtLcM3A4FRyPyqnsOaAGSTnzPQVesLhSSDWZL83IqW24PHFAHT26h40yAeaJbQhn28g8is+xuvKVQ543da6JWVgjdQR1oAyHjLRhsexr5/wDjJpiS+KLyb+Py4+P+ACvpSaBfLbH1r55+L29vGV3HH0CR/wDoAoA8FvImSVg4PBqAKOpxXf3ekxTxlnX5657UNGaJSUUkUAYDRB2AGOtSSWg2gKcVMIPIY+YcN6VIMODjNAGXJAyEnGR602IsG5BxWuYuOnNLFEHb5hwKAK2xTF86AlhgVVbSYZCTyprSkjDSYXt0q3BBjrjIoA5qTRiGyvPtVa40ibzBkYHvXb+WB/DmqF8iiSgDFtNK4zJj6V7N8BVWxuLsom6RuOOwrg9M08SxqzdPSu78AsNL1YiPrMpUD3oA9d1N5Z44JppAixyjdx15rrraZlmjMRCqycH1riniNzoM8E4IkT5z+FdFoF6t5pdtNF0QYJ+lAHnHxp0o3brqKriYfLLjv715tpVnz82K+mdd0+01TRp42jBMmck9c4r58ktWtbqaFlKlGK0AWoANoUDkVdAKrjHPeobGHoxFXxGzHIAoAdEhaPAHSrtuu2LDdagtFJcj07VorDtGD3GRQBCUAmVgMVt6cCFDZwTWOUZpFHbtW5p8RAUseKAOk0kM1b6jCjOKwtLJTPGB2rTEx3AUAW0iHmBh1ongbc3vTYJPmU9s1cuW+Yc8Y6UAZTW5Y4Ap0Vqcc8Ve35NK2NvXk0AVhbZ4HWtSziCW6L6Z/nVMeua0Lb/UL+P86APzX+IpJ8feJfT+07n/ANGtXO12vj7QdSk8deI3S2yjalcsDvXkGVvesH/hHdU/59f/ACIv+NAGSOtGK2B4c1TGfs3/AJEX/Gm/8I9qn/Pr/wCRF/xoAyaStgeHtUz/AMev/kRf8acvhzUyebb/AMiL/jQBkJkEVdis/NwV79q1IPDGoEjNv/4+v+NdHo3hm9jbLW2R7uv+NAGPpmn+SqsR8xrqdOizgGtWHw1eTAHyAP8Aga/41r6T4XvRMAYhgn++v+NAF3QLQpBuC9a6mzt1kUKww1XbXQZ4LVAqDj3FXrTSbjIOzHvkUAU47NlIG3j6VuaN50EoV8mM9R6Vcs9PmJCsn45FdDb6OpiBxg0AMtJbqxkWS0kbYTkpniu10rUVvYRuG2THIrmVs3QBVHT3q5aGW3bIH60AdVRVKzumkUCRcH1q7QBDdzrbW7yv0UVzl1MJxuf77c1o68GlEcQ+6DuNZflNuyV/WgByj93imonzEmrEcLEdOfrTnhbY2BzigDOnuNpIQ9KbJJutwWPJps0UgYjb+tAgke3IxyPegCuoG4VFL94nrVlYJCACOR70yS2cfw9fegCsv4jNWYR1Ge1NFvJ/dzj3FWIIXBPy9vWgCeOPMIJ9a6PTWP2VAeQOKx7eJmthkdK0rHesZB+tAGhICQMc9q8F+J9sz+MrvaP4Y/8A0AV71E24GvIfiJZzSeLLp40ypVMHI/uigDzufT1jg3d6w5oGkDBV4rvBpdxM4Vk+U/7Qqd/DRCFkjGfqKAPGL3Q5JZWY5NPs9GaNuVIA9a9Un0SSKIlYRuPuKypNHujljEOP9of40AcPPp8bk+WOe4qjNZ+QCAvNdsNCuDPv8rHr8w/xqnqWiXrP8kPH++P8aAOMjt8OCRyasBcA5FbLaJfDP7kZ7fOv+NA0S9bGYR7/ADj/ABoAx41J5GRT4NN+0zA44zWnJpN2owkGP+BL/jXRaRotwLVWaHk/7Q/xoAyo7ZYEVQOAO1SxM0cqSISGQgit06Rct/yy4/3h/jTTotyOfK/8eH+NAHq3hbVBrGgxRxovnsNrEitnR4ItMnew3iRmG7pgCuL+FnnWV1NFPFx1XkV1OrI6axHeLuADYKgjmgC1cadqF3erHa3CxIDznpXn3xD0GSw1wybQUkGdw6E16rKHDQToDkckZxUOu6aniLSpAUCTRAlWPrQB4pAmxMHFXolUp0pk2mXUNy8bJnBx94f41cttPuhjKcf7woASGHawI4rTSMNFkjmkj0+csPkAH1FasFk6xHKZP1FAGZFBh+RxWraoSwC1JHYyMfu/qK2NLsWDBio496AJLaFkSp0BGc1caFgo4pwhPp1oAhiZiwPvUl9MQ4A44qRYWJAxzmqt6si3JwueKAFSY5FWEfPXGaqQozPyMVeSPb0WgByHHFaVsP3C81UjiJ61oRRhYwKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiogram (ERC) image of the distal biliary tract in a patient who developed abnormal liver enzymes one month after liver transplantation. Panel A) The ERC shows a severe anastomotic stricture. Panel B) shows a thru-the scope (TTS) balloon being inserted across the stricture to dilate the anastomosis stricture. The stricture was dilated followed by placement of a plastic stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karen Krok, MD and Paul J Thuluvath, MBBS, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13425=[""].join("\n");
var outline_f13_7_13425=null;
var title_f13_7_13426="Patient information: Adenovirus infections (The Basics)";
var content_f13_7_13426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/13/27858\">",
"         Patient information: Rotavirus infection (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/23/37235\">",
"         Patient information: Fever in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40643\">",
"         Patient information: The common cold in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Adenovirus infections (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/adenovirus-infections-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7367943\">",
"      <span class=\"h1\">",
"       What are adenovirus infections?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Adenovirus infections are a group of infections caused by a type of virus called &ldquo;adenoviruses.&rdquo; Adenoviruses can infect different parts of the body. They cause many types of illnesses, including the common cold.",
"     </p>",
"     <p>",
"      Adenovirus infections are not serious in most people, but they can be serious in young babies and people who have trouble fighting infections. This includes people who have had organ or stem cell transplants, people with cancer, and people with HIV infection.",
"     </p>",
"     <p>",
"      Adenovirus infections happen more often in children than adults. They almost always cause a fever along with other symptoms. Adenovirus infections spread easily, so it is not unusual for there to be &ldquo;outbreaks&rdquo; of infections. For example, this can happen in daycare centers. People just starting in the military also tend to get adenovirus infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7367958\">",
"      <span class=\"h1\">",
"       What are the symptoms of adenovirus infections?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of adenovirus infections are different depending on what part of the body the virus infects. Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Runny nose",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Ear pain",
"       </li>",
"       <li>",
"        Conjunctivitis (also called &ldquo;pinkeye&rdquo;)",
"       </li>",
"       <li>",
"        Diarrhea",
"       </li>",
"       <li>",
"        Hoarse voice",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7367973\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you do not have trouble fighting infections, then probably not. Adenovirus infections usually get better on their own. But if any of your symptoms are severe or last longer than a few days, you should see your doctor or nurse.",
"     </p>",
"     <p>",
"      You should also see your doctor or nurse if you have trouble fighting infections. For example, see your doctor or nurse if you have had an organ or stem cell transplant or if you have cancer or HIV infection.",
"     </p>",
"     <p>",
"      The symptoms of adenovirus infection can also happen with more serious infections. To make sure that your child does not have one of these more serious infections, you should take your child to a doctor or nurse if he or she is:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Younger than 3 months and has a rectal temperature of 100.4&ordm;F (38&ordm;C) or higher. Your infant should see a doctor or nurse even if he or she looks normal or seems fine.",
"       </li>",
"       <li>",
"        Between 3 and 36 months and has a rectal temperature of 100.4&ordm;F (38&ordm;C) or higher for more than 3 days. Go right away of your child seems sick or is fussy, clingy, or refuses to drink fluids.",
"       </li>",
"       <li>",
"        Between 3 and 36 months old and has a rectal temperature of 102&ordm;F (38.9&ordm;C) or higher.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Children of any age should also see a doctor or nurse if they have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An oral, rectal, ear, or forehead temperature of 104&ordm;F (40&ordm;C) or higher",
"       </li>",
"       <li>",
"        An armpit temperature of 103&ordm;F (39.4&ordm;C) or higher",
"       </li>",
"       <li>",
"        A seizure caused by a fever",
"       </li>",
"       <li>",
"        Fevers that keep coming back (even if they last only a few hours)",
"       </li>",
"       <li>",
"        A fever as well as an ongoing medical problem, such as heart disease, cancer, lupus, or sickle cell anemia",
"       </li>",
"       <li>",
"        A fever as well as a new skin rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7367988\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. But if your symptoms or your child&rsquo;s symptoms are severe, the doctor might do tests to find out the cause of the infection. He or she might also order tests if lots of people in your area get the same type of infection. For example, doctors might do tests if lots of children at the same summer camp get an eye infection along with a sore throat and fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7368003\">",
"      <span class=\"h1\">",
"       How are adenovirus infections treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Adenovirus infections usually get better on their own without any treatment. But these infections can be serious in young babies or people who have problems fighting infections. In rare cases, doctors prescribe medicines that fight viruses. These are called &ldquo;anti-viral medicines.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7368018\">",
"      <span class=\"h1\">",
"       Can adenovirus infections be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best way to prevent an adenovirus infection is to keep your hands clean. Wash your hands often with soap and water or alcohol gel rubs.",
"     </p>",
"     <p>",
"      Some other ways to prevent the spread of infection are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Always wash your hands with soap and water after you change your child&rsquo;s diaper.",
"       </li>",
"       <li>",
"        Clean sinks, counters, and other surfaces with a bleach and water mixture.",
"       </li>",
"       <li>",
"        Do not share towels, bed linens, pajamas, or other personal items.",
"       </li>",
"       <li>",
"        Cover your mouth when you sneeze or cough.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7368033\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=see_link\">",
"       Patient information: Rotavirus infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       Patient information: Fever in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=see_link\">",
"       Patient information: The common cold in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/7/13426?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83054 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-965172F715-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13426=[""].join("\n");
var outline_f13_7_13426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7367943\">",
"      What are adenovirus infections?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7367958\">",
"      What are the symptoms of adenovirus infections?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7367973\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7367988\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7368003\">",
"      How are adenovirus infections treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7368018\">",
"      Can adenovirus infections be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7368033\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=related_link\">",
"      Patient information: Rotavirus infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40643?source=related_link\">",
"      Patient information: The common cold in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_7_13427="Patient information: Cough in children (The Basics)";
var content_f13_7_13427=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16897\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/23/29044\">",
"         Lungs in a healthy child",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/31/27121\">",
"          Signs of severe trouble breathing (retractions)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/28/24002\">",
"         Patient information: Acute bronchitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/58/17315\">",
"         Patient information: Asthma in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/10/39074\">",
"         Patient information: Bronchiolitis (and RSV) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/55/18291\">",
"         Patient information: Cough, runny nose, and the common cold (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/43/22195\">",
"         Patient information: Coughing up blood (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/63/32754\">",
"         Patient information: Croup (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/38/36450\">",
"         Patient information: Whooping cough (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/0/37892\">",
"         Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/19/27958\">",
"         Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/28/2500\">",
"         Patient information: Croup in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Cough in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cough-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7868655\">",
"      <span class=\"h1\">",
"       What is a cough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A cough is an important reflex that helps clear out the body&rsquo;s airways (the branching tubes that carry air within the lungs). Coughing also helps keep people from breathing things into the airways and lungs that could cause problems (",
"      <a class=\"graphic graphic_figure graphicRef56535 \" href=\"UTD.htm?28/23/29044\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      It is normal for children to cough once in a while. But sometimes, a cough is a symptom of an illness or condition.",
"     </p>",
"     <p>",
"      Coughs are called &ldquo;dry&rdquo; if they don&rsquo;t bring up mucus, and &ldquo;wet&rdquo; if they do. The sound of your child&rsquo;s cough can be different depending on if it is wet or dry. Some coughs are mild, but others are severe. A severe cough can make it hard to breathe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7868670\">",
"      <span class=\"h1\">",
"       What causes a cough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common causes of a cough in children are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Infections of the airways or lungs (including the common cold)",
"       </li>",
"       <li>",
"        Having an object stuck in an airway",
"       </li>",
"       <li>",
"        Asthma &ndash; This is a lung condition that can make it hard to breathe.",
"       </li>",
"       <li>",
"        Other lung problems, including conditions that some children are born with",
"       </li>",
"       <li>",
"        Coughing out of habit. This type of cough usually goes away when a child is sleeping.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7868685\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See the doctor or nurse right away if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Is younger than 3 months old",
"       </li>",
"       <li>",
"        Is having trouble breathing, has noisy breathing, or is breathing very fast (",
"        <a class=\"graphic graphic_figure graphicRef59786 \" href=\"UTD.htm?26/31/27121\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Gets a cough after he or she choked on food or another object, even if he or she choked on the object days or weeks ago",
"       </li>",
"       <li>",
"        Is coughing up blood, or yellow or green mucus",
"       </li>",
"       <li>",
"        Refuses to drink anything for a long time",
"       </li>",
"       <li>",
"        Has a fever and is not acting like him- or herself",
"       </li>",
"       <li>",
"        Is coughing so hard that he or she vomits",
"       </li>",
"       <li>",
"        Has had the cough for more than 2 weeks",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7868700\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The doctor or nurse will ask questions about your child&rsquo;s symptoms and examine him or her. He or she might do tests, depending on your child&rsquo;s age and other symptoms. There are different tests doctors can do to see what&rsquo;s causing a cough. The most common ones include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A chest X-ray",
"       </li>",
"       <li>",
"        Tests to check for an infection &ndash; For example, the doctor can use a cotton swab to collect a sample from the inside of your child&rsquo;s nose or throat. Then he or she will do lab tests on the sample.",
"       </li>",
"       <li>",
"        Breathing tests &ndash; Breathing tests involve breathing hard into a tube. These tests show how the lungs are working. Most children 6 years old and older are able to do breathing tests.",
"       </li>",
"       <li>",
"        Bronchoscopy &ndash; This is a procedure in which a doctor uses a thin tube with a camera on the end (called a &ldquo;bronchoscope&rdquo;) to look inside your child&rsquo;s airways. If the doctor finds an object stuck in your child&rsquo;s airway, he or she can remove it during this procedure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7868715\">",
"      <span class=\"h1\">",
"       Is there anything I can do to help get rid of my child&rsquo;s cough?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child&rsquo;s cough is from a cold, the croup, or another infection, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have him or her drink lots of fluids.",
"       </li>",
"       <li>",
"        Use a humidifier in his or her bedroom.",
"       </li>",
"       <li>",
"        Sit in the bathroom with him or her while you run hot water in the shower.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are certain things you should NOT do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do NOT give over-the-counter cough and cold medicines to children, especially if they are younger than 6 years old. Cough and cold medicines are not likely to help, and they can cause serious problems in young children.",
"       </li>",
"       <li>",
"        Do NOT give",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        to children younger than 18 years old. Aspirin can cause a life-threatening condition called Reye syndrome in young people.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7868730\">",
"      <span class=\"h1\">",
"       How is a cough treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the cause of your child&rsquo;s cough. For example:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Some infections are treated with antibiotic medicines. If an infection is caused by bacteria, doctors can treat it with antibiotics. If an infection is caused by a virus (such as the common cold), doctors cannot treat it with antibiotics.",
"       </li>",
"       <li>",
"        Asthma is treated with medicines that a child breathes into his or her lungs.",
"       </li>",
"       <li>",
"        If your child has an object stuck in his or her airway, the doctor can do bronchoscopy to look for it and remove it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors do not usually prescribe medicines that quiet a cough to children. These medicines don&rsquo;t usually work well, and they can have serious side effects in children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7868745\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=see_link\">",
"       Patient information: Cough, runny nose, and the common cold (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=see_link\">",
"       Patient information: Acute bronchitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"       Patient information: Asthma in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/10/39074?source=see_link\">",
"       Patient information: Bronchiolitis (and RSV) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/63/32754?source=see_link\">",
"       Patient information: Croup (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=see_link\">",
"       Patient information: Whooping cough (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"       Patient information: Coughing up blood (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"       Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/19/27958?source=see_link\">",
"       Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/28/2500?source=see_link\">",
"       Patient information: Croup in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/7/13427?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16897 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13427=[""].join("\n");
var outline_f13_7_13427=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868655\">",
"      What is a cough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868670\">",
"      What causes a cough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868685\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868700\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868715\">",
"      Is there anything I can do to help get rid of my child&rsquo;s cough?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868730\">",
"      How is a cough treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7868745\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/23/29044\">",
"      Lungs in a healthy child",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/31/27121\">",
"       Signs of severe trouble breathing (retractions)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=related_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=related_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=related_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/10/39074?source=related_link\">",
"      Patient information: Bronchiolitis (and RSV) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/19/27958?source=related_link\">",
"      Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/55/18291?source=related_link\">",
"      Patient information: Cough, runny nose, and the common cold (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=related_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/63/32754?source=related_link\">",
"      Patient information: Croup (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/28/2500?source=related_link\">",
"      Patient information: Croup in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/38/36450?source=related_link\">",
"      Patient information: Whooping cough (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_7_13428="Levocetirizine: Patient drug information";
var content_f13_7_13428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levocetirizine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=see_link\">",
"     see \"Levocetirizine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/63/9205?source=see_link\">",
"     see \"Levocetirizine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5183881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xyzal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hives.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to levocetirizine, cetirizine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the evening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11981 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13428=[""].join("\n");
var outline_f13_7_13428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5183881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022454\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022453\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022458\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022459\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022461\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022456\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022457\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022462\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022463\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/45/44757?source=related_link\">",
"      Levocetirizine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/63/9205?source=related_link\">",
"      Levocetirizine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_7_13429="PTSD checklist military";
var content_f13_7_13429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65285&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    PTSD checklist - military version (PCL-M)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 786px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A score &ge;50 suggests the possibility of PTSD. The diagnosis of PTSD requires further confirmation by clinician interview.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Weathers, FW, Huska, JA, Keane, TM. PLC-M for DSM-IV. Boston: National Center for PTSD - Behavioral Science Division, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13429=[""].join("\n");
var outline_f13_7_13429=null;
var title_f13_7_13430="Lymphocyte and monocyte";
var content_f13_7_13430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cells in peripheral smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear shows four different leukocytes: a band form, a lymphocyte, a monocyte, and a metamyelocyte. The lymphocyte is a small cell with a heavily stained condensed nucleus and a small rim of blue cytoplasm. The monocyte has an irregular nucleus with grayish, blue cytoplasm that has few granules. The metamyelocyte has a kidney bean-shaped nucleus with a granulated cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13430=[""].join("\n");
var outline_f13_7_13430=null;
var title_f13_7_13431="Reverse typical atrial flutter";
var content_f13_7_13431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Reverse typical atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram in type I clockwise typical atrial flutter. The flutter waves are positive in the inferior leads (II, III, aVF), with a more sinusoidal appearance and a broad negative F wave in V1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13431=[""].join("\n");
var outline_f13_7_13431=null;
var title_f13_7_13432="Overview of the treatment of testicular germ cell tumors";
var content_f13_7_13432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13432/contributors\">",
"     William K Oh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13432/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13432/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/7/13432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers are one of the most curable solid neoplasms. The five-year survival rate is over 95 percent, and fewer than 400 deaths from testicular cancer are seen in the United States per year [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13432/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Initial therapy of early-stage testicular germ cell tumors (GCTs) is based upon histology and tumor extent (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An overview of therapy for men with testicular GCTs will be presented here. The clinical manifestations, diagnosis, and staging are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview of treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with testicular cancer undergo a radical inguinal orchiectomy at the time of initial presentation for diagnosis and definitive treatment.",
"   </p>",
"   <p>",
"    For men who present with clinically advanced disease, we prefer to perform a radical orchiectomy prior to chemotherapy whenever possible. Despite this usual approach, there are some men who present with life-threatening advanced disease who undergo systemic chemotherapy prior to orchiectomy (&ldquo;delayed orchiectomy&rdquo;). In such patients, the diagnosis is obtained by biopsy of a metastatic lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The final pathologic information is used to stratify treatment by histology. There are two forms of testicular germ cell tumors: non-seminomatous germ cell tumors (NSGCTs) and seminomas. They differ by their clinical and biologic behavior.",
"   </p>",
"   <p>",
"    Compared to NSGCTs, seminomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are more likely to present with localized disease. Approximately 80 percent of men with seminomas present with stage I disease (limited to the testicle), while 15 percent have stage II disease (limited to retroperitoneal nodes) (",
"      <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"       table 2",
"      </a>",
"      ). Fewer than five percent of patients have spread beyond the retroperitoneal nodes at presentation.",
"     </li>",
"     <li>",
"      Rarely spread via the bloodstream to other areas (eg, liver, lung, bones, or brain). This occurs more commonly in men with NSGCT.",
"     </li>",
"     <li>",
"      Are exquisitely sensitive to radiation therapy (RT) while NSGCTs are more radioresistant.",
"     </li>",
"     <li>",
"      Are usually not marked by elevations in serum tumor markers at presentation or with recurrence. In contrast, serum beta-hCG (&beta;-hCG) and alpha fetoprotein (AFP) are elevated in with the majority of men with NSGCTs. Men with pure seminoma never have an elevated AFP. Seminoma occurring in the context of an elevated serum AFP is considered a mixed GCT. These cancers are treated as a NSGCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"       \"Serum tumor markers in testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Display relatively indolent growth and a longer natural history.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647557957\">",
"    <span class=\"h1\">",
"     FERTILITY AND SPERM BANKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, a baseline sperm count and sperm banking should be performed prior to diagnosis and staging in order to avoid treatment exposure of the sperm. Semen cryopreservation should be made available to all men diagnosed with testicular cancer prior to instituting therapy if they wish to preserve fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Cryopreservation of sperm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EARLY-STAGE DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647554843\">",
"    <span class=\"h2\">",
"     Seminoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Stage I seminoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with stage I seminoma (",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"     table 2",
"    </a>",
"    ), orchiectomy is usually curative. The options for post-surgical management include active surveillance, radiation therapy (RT) to paraaortic lymph nodes, or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for two cycles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"     \"Treatment of stage I seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are able to comply with follow-up, we suggest active surveillance rather than chemotherapy or adjuvant RT. Given their excellent prognosis, active surveillance spares men from the risks of treatment-associated morbidity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"       \"Treatment of stage I seminoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H77783068#H77783068\">",
"       \"Treatment of stage I seminoma\", section on 'Active surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men who refuse active surveillance and those who want more aggressive treatment (despite their excellent prognosis), we suggest single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      rather than adjuvant RT. Single agent carboplatin is well tolerated and as effective as adjuvant RT in preventing relapse. It is also associated with less morbidity, including lower risks of impaired fertility, second malignancy, or late cardiac disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H77783835#H77783835\">",
"       \"Treatment of stage I seminoma\", section on 'Men who decline active surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men who refuse active surveillance and those who are not candidates for chemotherapy, we suggest adjuvant RT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link&amp;anchor=H77783835#H77783835\">",
"       \"Treatment of stage I seminoma\", section on 'Men who decline active surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Stage II seminoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following orchiectomy, the optimal treatment for stage II disease depends upon whether there is bulky lymph node involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"     \"Treatment of stage II seminoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nonbulky lymphadenopathy",
"      </strong>",
"      &mdash; For men with nonbulky adenopathy (ie, diameter of involved nodes less than three to five cm), we suggest adjuvant RT rather than chemotherapy. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy is a reasonable alternative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of stage II seminoma\", section on 'Nonbulky (stage IIA/IIB) disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bulky lymphadenopathy",
"      </strong>",
"      &mdash; For men with bulky retroperitoneal adenopathy (ie, maximum diameter of involved nodes greater than five cm), we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of stage II seminoma\", section on 'Bulky (stage IIB/IIC) seminoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Elevated &beta;-hCG",
"      </strong>",
"      &mdash; Although uncommon, men with pure seminoma may have associated elevations in serum &beta;-hCG (&gt;50",
"      <span class=\"nowrap\">",
"       IU/L).",
"      </span>",
"      While its clinical significance is controversial, we suggest treatment using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of stage II seminoma\", section on 'Pure seminoma with elevated tumor markers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal regimen has not been defined. Two options are equally effective: three courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP) or four courses of etoposide plus cisplatin (EP). A choice between them should be based on institutional practice and the predicted ability of the patient to tolerate bleomycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647555688\">",
"    <span class=\"h2\">",
"     Non-seminomatous germ cell tumor",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647555710\">",
"    <span class=\"h3\">",
"     Stage I NSGCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with stage I NSGCT, management depends on whether or not certain factors that predict an increased risk of relapse are present. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphovascular invasion",
"     </li>",
"     <li>",
"      Predominance of an embryonal carcinoma component",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Using these risk factors, our approach to men with stage I NSGCT is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who do not have any risk factors present have low-risk disease and we suggest active surveillance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H2#H2\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men with either of these risk factors present have high-risk disease. Active surveillance, chemotherapy, or retroperitoneal lymph node dissection (RPLND) are all options. If technical expertise is available, RPLND is an appropriate treatment option. However, chemotherapy (one cycle of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) is a reasonable alternative. For men who prefer not to undergo further treatment, active surveillance is a reasonable alternative. However, these men should understand their risk of relapse approaches 40 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"       \"Management of stage I nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647555346\">",
"    <span class=\"h3\">",
"     Stage II NSGCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with stage II NSGCT, treatment depends upon whether disease is documented pathologically or clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link\">",
"     \"Management of stage II nonseminomatous germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pathologic stage II NSGCT",
"      </strong>",
"      &mdash; Men with NSGCT with confirmed pathological node involvement following RPLND have pathologic stage II NSGCT (",
"      <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"       table 2",
"      </a>",
"      ). Treatment following RPLND is based on the extent of nodal involvement (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of stage II nonseminomatous germ cell tumors\", section on 'Pathologic stage IIA disease'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with nodal metastasis &le;2 cm in greatest diameter, we suggest surveillance. While adjuvant chemotherapy dramatically reduces the relapse rate, treatment has no significant effect on survival because patients who relapse are treated with chemotherapy for curative intent. &nbsp;",
"     </li>",
"     <li>",
"      For men with nodal involvement &gt;2 cm, we suggest adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy because the relapse risk is relatively higher.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clinical stage IIA NSGCT",
"      </strong>",
"      &mdash; For men with radiographically detected nodal disease &lt;2 cm and normal serum tumor markers, we suggest RPLND. Further treatment would be determined by pathologic stage as discussed above. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=see_link&amp;anchor=H18#H18\">",
"       \"Retroperitoneal lymph node dissection in testicular germ cell tumors\", section on 'Role of RPLND-II'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical stage IIB and IIC NSGCT",
"      </strong>",
"      &mdash; For men with radiographically detected nodal disease &ge;2 cm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      elevated serum tumor markers, we suggest primary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , plus cisplatin (BEP) for three cycles or etoposide plus cisplatin (EP) for four cycles are acceptable regimens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link&amp;anchor=H8532060#H8532060\">",
"       \"Management of stage I nonseminomatous germ cell tumors\", section on 'Retroperitoneal lymph node dissection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H389222551\">",
"    <span class=\"h1\">",
"     ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with advanced (stage III to IV) testicular GCT, management does not differ by histologic type. Instead, treatment is selected based upon the International Germ Cell Cancer Collaborative Group (IGCCCG) risk stratification system (",
"    <a class=\"graphic graphic_table graphicRef61906 \" href=\"UTD.htm?41/46/42732\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=see_link\">",
"     \"Risk stratification of metastatic testicular germ cell tumors\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    The IGCCCG system takes into account the primary tumor site, metastatic disease, and serum tumor marker levels. Men with seminoma are categorized as having good or intermediate risk. Men with NSGCT fall into one of three categories: good risk, intermediate risk, or poor risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340146498\">",
"    <span class=\"h2\">",
"     Good risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with seminoma:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Any primary site",
"     </li>",
"     <li>",
"      No metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Normal serum AFP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with NSGCT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testicular or retroperitoneal primary tumors",
"     </li>",
"     <li>",
"      No metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Serum AFP &lt;1000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      &beta;-hCG &lt;5000 milli-international units",
"      <span class=\"nowrap\">",
"       (mIU)/mL,",
"      </span>",
"      and LDH &lt;1.5 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340146506\">",
"    <span class=\"h2\">",
"     Intermediate risk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with seminoma:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testicular or retroperitoneal primary",
"     </li>",
"     <li>",
"      Metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Normal serum AFP",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with NSGCT:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Testicular or retroperitoneal primary",
"     </li>",
"     <li>",
"      No metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Any of the following: serum AFP 1000 to 10,000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      &beta;-hCG 5000 to 50,000",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      LDH 1.5 to 10 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340146514\">",
"    <span class=\"h2\">",
"     Poor risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor risk is used to characterize a third group of men with NSGCT. It does not apply to men with seminoma. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with NSGCT only, any of the following constitutes poor risk:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mediastinal primary site with or without metastases",
"     </li>",
"     <li>",
"      Metastases to organs other than the lungs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lymph nodes",
"     </li>",
"     <li>",
"      Serum AFP &gt;10,000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      serum beta-hCG &gt;50,000",
"      <span class=\"nowrap\">",
"       mIU/mL,",
"      </span>",
"      LDH &gt;10 times upper limit of normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647557608\">",
"    <span class=\"h2\">",
"     Treatment by risk group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to advanced disease depends on the risk group as defined above, rather than by the histologic subtype of testicular cancer (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"     \"Surgical management of advanced testicular germ cell tumors\"",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104979121\">",
"    <span class=\"h3\">",
"     Good-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with good-risk disease, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy. Our standard treatment is three cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and cisplatin (BEP). However, men with compromised pulmonary function who are at risk for bleomycin-induced lung injury should be treated with etoposide and cisplatin (EP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Good-risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104979130\">",
"    <span class=\"h3\">",
"     Intermediate- or poor-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with intermediate-risk or poor-risk disease, we recommend four cycles of BEP. An alternative regimen consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (VIP), which is preferred for patients at risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    -induced lung injury.",
"   </p>",
"   <p>",
"    Although high-dose chemotherapy with autologous stem cell transplantation is a promising approach, we suggest not administering high-dose chemotherapy as first-line treatment for poor-risk GCTs outside of a clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\", section on 'Intermediate- and poor-risk advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following adjuvant treatment, a posttreatment CT scan should be obtained. This is particularly important for men who had initial evidence of retroperitoneal adenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444002858\">",
"    <span class=\"h1\">",
"     MANAGEMENT AFTER PRIMARY TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of men after post-orchiectomy treatment depends on the histologic type of GCT and whether residual disease:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615046502\">",
"    <span class=\"h2\">",
"     Seminoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest posttreatment surveillance if there is no evidence of residual disease. In addition, we suggest posttreatment surveillance rather than surgical resection if there is any residual mass &lt;3 cm in size. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of stage II seminoma\", section on 'Post therapy residual masses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We perform a PET scan if there is evidence of residual masses &ge;3 cm to determine appropriate treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the PET scan is negative, we suggest posttreatment surveillance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of stage II seminoma\", section on 'Post therapy residual masses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A positive PET scan indicates the presence of residual disease. In this situation, we suggest resection. Following resection of residual masses that contain viable GCT, we suggest two additional courses of chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link\">",
"       \"Surgical management of advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If resection of residual disease is not technically feasible, we recommend surveillance. Second-line chemotherapy should be deferred until there is evidence of disease progression by imaging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615046575\">",
"    <span class=\"h2\">",
"     NSGCT",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men who have normalized their serum tumor markers but have imaging evidence of &ge;1 retroperitoneal lymph nodes larger than 1 cm, we perform a RPLND. If RPLND is not performed, we proceed with posttreatment surveillance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H7#H7\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'Nonseminomatous GCTs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no consensus on the best approach to manage men with persistently elevated serum tumor markers that are either stable or sluggishly declining at the end of treatment. Although they are at a high risk of relapse, we do not suggest administration of additional chemotherapy. We offer either postchemotherapy RPLND or surveillance. A choice depends on patient preference and whether the expertise to perform a RPLND is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'RPLND after chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444003630\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic surveillance of the serum concentrations of &beta;-hCG and AFP is the most sensitive means of detecting early relapse for men with NSGCT.",
"   </p>",
"   <p>",
"    For men with seminoma, the value of monitoring serum tumor markers is of unclear value, as relapse is almost always detected by exam or by imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients who relapse do so within the first one to two years after their initial treatment. Late relapses (after five years) can occur but are rare. The intensity of follow-up is dictated by the histology of the original tumor (seminoma versus nonseminomatous GCT), and the stage and risk of recurrence at original presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=see_link\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED OR REFRACTORY GCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of relapsed GCTs depends upon the response to prior therapy, the location and timing of the relapse, and tumor histology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link\">",
"     \"Treatment of relapsed and refractory testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who are chemotherapy-naive at the time of recurrence should be treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination regimen (BEP or EP). RPLND is an alternative to chemotherapy in properly selected patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H14685207#H14685207\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Chemotherapy-naive patients'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      For men who relapse following post-orchiectomy chemotherapy, we recommend combination chemotherapy using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (VIP). Other options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with ifosfamide, plus cisplatin (VeIP or TIP).",
"     </li>",
"     <li>",
"      For men who were not previously treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , we suggest VIP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H109606309#H109606309\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Chemotherapy for initial relapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men who relapse during or within four weeks after initial chemotherapy have platinum-refractory disease. These men should be treated on a high-dose chemotherapy protocol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H196220871#H196220871\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Platinum-refractory disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late-relapsing tumors are uncommon and tend to grow slowly. Treatment consists of an aggressive surgical approach and systemic chemotherapy. Surgical resection appears to be crucial for long-term survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H18#H18\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Late relapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain metastases may present as an isolated manifestation of metastatic disease or in conjunction with other systematic metastases. Systemic chemotherapy is usually preferred for initial treatment. However, in selected cases, chemotherapy may be used in combination with brain radiation therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical resection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Brain metastases'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/51/31538?source=see_link\">",
"       \"Patient information: Testicular cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24645?source=see_link\">",
"       \"Patient information: Testicular cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testicular germ cell tumors (GCTs) are among the most curable solid neoplasms, with five-year survival rates of approximately 95 percent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Semen cryopreservation should be made available to all men diagnosed with testicular cancer prior to instituting therapy if they wish to preserve fertility. Whenever possible, a baseline sperm count and sperm banking should be performed prior to diagnosis and staging in order to avoid radiation exposure of the sperm. (See",
"      <a class=\"local\" href=\"#H647557957\">",
"       'Fertility and sperm banking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal therapy requires estimating the likelihood of recurrence, so that therapy can be limited, when appropriate. Key elements in risk stratification include histology (ie, seminoma versus nonseminomatous germ cell tumor [NSGCT]), the presence or absence of metastases, and the degree of elevation in serum tumor markers (",
"      <a class=\"graphic graphic_table graphicRef82117 \" href=\"UTD.htm?35/13/36061\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef56341 \" href=\"UTD.htm?20/34/21037\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104979141\">",
"    <span class=\"h2\">",
"     Early stage seminoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a stage I seminoma, an extremely high cure rate can be achieved with radical orchiectomy. This may be followed by active surveillance, RT to paraaortic lymph nodes, or single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      chemotherapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stage I seminoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=see_link\">",
"       \"Treatment of stage I seminoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men with stage II seminoma are usually managed with radiation therapy (RT) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy depending upon the extent of retroperitoneal disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stage II seminoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link\">",
"       \"Treatment of stage II seminoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104979149\">",
"    <span class=\"h2\">",
"     Early stage nonseminoma germ cell tumors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with stage I NSGCT, the management approach is based on the presence or absence of specific risk factors for recurrence: vascular or lymphatic invasion, embryonal carcinoma comprising &gt;40 percent of the total tumor volume, the presence of yolk sac elements, or elevated serum tumor markers prior to orchiectomy that do not decreased by expected half-life. (See",
"      <a class=\"local\" href=\"#H647555710\">",
"       'Stage I NSGCT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"       \"Management of stage I nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men who do not have any risk factors present, we suggest active surveillance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=see_link&amp;anchor=H2#H2\">",
"       \"Active surveillance following orchiectomy for stage I testicular germ cell tumors\", section on 'General principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with risk factors, we suggest a retroperitoneal lymph node dissection (RPLND). However, two cycles of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based regimen is a reasonable alternative to surgery and is frequently the treatment of choice in Europe. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=see_link\">",
"       \"Management of stage I nonseminomatous germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with stage II NSGCT, treatment depends upon the extent of disease and whether retroperitoneal lymph node involvement is documented pathologically or is based upon imaging studies. Treatment options include RPLND, surveillance, or the use of combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy. (See",
"      <a class=\"local\" href=\"#H647555346\">",
"       'Stage II NSGCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444003136\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men with advanced disease are classified into good-, intermediate-, and poor-risk (only for NSGCT) groups using the International Germ Cell Cancer Collaborative Group (IGCCCG) risk stratification system (",
"      <a class=\"graphic graphic_table graphicRef61906 \" href=\"UTD.htm?41/46/42732\">",
"       table 3",
"      </a>",
"      ). The IGCCCG system takes into account the primary tumor site, metastatic disease, and serum tumor marker levels. (See",
"      <a class=\"local\" href=\"#H389222551\">",
"       'Advanced disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"       \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men with good-risk disease, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination chemotherapy. Our standard treatment is three cycles of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and cisplatin (BEP). However, men with compromised pulmonary function who are at risk for bleomycin-induced lung injury should be treated with etoposide and cisplatin (EP).",
"     </li>",
"     <li>",
"      For men with intermediate-risk or poor-risk disease, we recommend four cycles of BEP. An alternative regimen consists of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (VIP) is preferred for patients at risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      -induced lung injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444003514\">",
"    <span class=\"h2\">",
"     Management after primary treatment",
"    </span>",
"   </p>",
"   <p>",
"    Following adjuvant treatment, a posttreatment CT scan should be obtained. This is particularly important for men who had initial evidence of retroperitoneal adenopathy. (See",
"    <a class=\"local\" href=\"#H444002858\">",
"     'Management after primary treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with seminoma with evidence of residual disease &lt;3 cm in size, we suggest posttreatment surveillance rather than surgical resection. We perform a PET scan to better characterize residual masses &ge;3 cm. (See",
"      <a class=\"local\" href=\"#H615046502\">",
"       'Seminoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the PET scan is negative, we suggest posttreatment surveillance.",
"     </li>",
"     <li>",
"      If the PET scan is positive, we suggest resection of residual disease. If resection is not technically feasible, we suggest surveillance rather than initiation of second-line chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=see_link&amp;anchor=H10#H10\">",
"       \"Treatment of stage II seminoma\", section on 'Post therapy residual masses'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H30\">",
"       'Treatment of relapsed or refractory GCT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with NSGCT, residual masses are commonly seen on postchemotherapy imaging studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For men who have normalized their serum tumor markers following treatment but have imaging evidence of &ge;1 retroperitoneal lymph nodes larger than 1 cm in diameter, an RPLND should be performed. If RPLND is not performed, we proceed with posttreatment surveillance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H7#H7\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'Nonseminomatous GCTs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with persistently elevated serum tumor markers that are either stable or sluggishly declining at the end of treatment, we offer either postchemotherapy RPLND or surveillance. A choice depends on patient preference and whether the expertise to perform a RPLND is available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgical management of advanced testicular germ cell tumors\", section on 'RPLND after chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615046627\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic surveillance of the serum concentrations of beta-hCG and AFP is the most sensitive means of detecting early relapse for men with NSGCT. For men with seminoma, the value of monitoring serum tumor markers is of unclear value, as relapse is almost always detected by exam or by imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H444003637\">",
"    <span class=\"h2\">",
"     Treatment of relapsed or refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of relapsed GCTs depends upon the response to prior therapy, the location and timing of the relapse, and tumor histology. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Treatment of relapsed or refractory GCT'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who are chemotherapy-naive at the time of recurrence should be treated with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination regimen (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , cisplatin). A RPLND is an alternative to chemotherapy in properly selected patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H14685207#H14685207\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Chemotherapy-naive patients'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      For men who relapse following post-orchiectomy chemotherapy, we administer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (VIP), particularly in men who were not previously treated with etoposide. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H109606309#H109606309\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Chemotherapy for initial relapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Men who relapse during or within four weeks after initial chemotherapy have platinum-refractory disease. These men should undergo high-dose chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H196220871#H196220871\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Platinum-refractory disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Late relapses (ie, after two years) are uncommon. An aggressive surgical approach in addition to systemic therapy should be adopted in these patients, since resection appears to be crucial to achieving long-term survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=see_link&amp;anchor=H18#H18\">",
"       \"Treatment of relapsed and refractory testicular germ cell tumors\", section on 'Late relapse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute, Bethesda, MD, 2004 file://seer.cancer.gov/csr/1975_2007/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13432/abstract/2\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2960 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-83.177.194.223-190351C039-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13432=[""].join("\n");
var outline_f13_7_13432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview of treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H647557957\">",
"      FERTILITY AND SPERM BANKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EARLY-STAGE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647554843\">",
"      Seminoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Stage II seminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647555688\">",
"      Non-seminomatous germ cell tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H647555710\">",
"      - Stage I NSGCT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H647555346\">",
"      - Stage II NSGCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H389222551\">",
"      ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340146498\">",
"      Good risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340146506\">",
"      Intermediate risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340146514\">",
"      Poor risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647557608\">",
"      Treatment by risk group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104979121\">",
"      - Good-risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H104979130\">",
"      - Intermediate- or poor-risk disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444002858\">",
"      MANAGEMENT AFTER PRIMARY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615046502\">",
"      Seminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615046575\">",
"      NSGCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H444003630\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TREATMENT OF RELAPSED OR REFRACTORY GCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104979141\">",
"      Early stage seminoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104979149\">",
"      Early stage nonseminoma germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444003136\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444003514\">",
"      Management after primary treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615046627\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H444003637\">",
"      Treatment of relapsed or refractory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/13/36061\" title=\"table 1\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/34/21037\" title=\"table 2\">",
"      Stage group testicular CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/46/42732\" title=\"table 3\">",
"      Risk strat system advancted TGCTs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3334?source=related_link\">",
"      Active surveillance following orchiectomy for stage I testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26070?source=related_link\">",
"      Management of stage I nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/19/10550?source=related_link\">",
"      Management of stage II nonseminomatous germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24645?source=related_link\">",
"      Patient information: Testicular cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/51/31538?source=related_link\">",
"      Patient information: Testicular cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/17/24852?source=related_link\">",
"      Risk stratification of metastatic testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38425?source=related_link\">",
"      Surgical management of advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2954?source=related_link\">",
"      Treatment of relapsed and refractory testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22567?source=related_link\">",
"      Treatment of stage I seminoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/45/22230?source=related_link\">",
"      Treatment of stage II seminoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_7_13433="Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults";
var content_f13_7_13433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13433/contributors\">",
"     Thomas M File, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13433/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13433/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/7/13433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospital-acquired (or nosocomial) pneumonia (HAP), ventilator-associated pneumonia (VAP), and healthcare-associated pneumonia (HCAP) are important causes of morbidity and mortality despite improved antimicrobial therapy, supportive care, and prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/1\">",
"     1",
"    </a>",
"    ]. The risk factors and prevention of HAP, VAP, and HCAP will be reviewed here.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, epidemiology, pathogenesis, microbiology, and treatment of HAP, VAP, and HCAP are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=see_link\">",
"     \"Clinical presentation and diagnosis of ventilator-associated pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pneumonia types",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 America Thoracic",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Disease Society of America",
"    <span class=\"nowrap\">",
"     (ATS/IDSA)",
"    </span>",
"    guidelines distinguish the following types of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospital-acquired (or nosocomial) pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission and did not appear to be incubating at the time of admission.",
"     </li>",
"     <li>",
"      Ventilator-associated pneumonia (VAP) is a type of HAP that develops more than 48 to 72 hours after endotracheal intubation.",
"     </li>",
"     <li>",
"      Healthcare-associated pneumonia (HCAP) is defined as pneumonia that occurs in a non-hospitalized patient with extensive healthcare contact, as defined by one or more of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days",
"     </li>",
"     <li>",
"      Residence in a nursing home or other long-term care facility",
"     </li>",
"     <li>",
"      Hospitalization in an acute care hospital for two or more days within the prior 90 days",
"     </li>",
"     <li>",
"      Attendance at a hospital or hemodialysis clinic within the prior 30 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HCAP was added as a category of pneumonia in the 2005",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    guidelines in order to identify patients at increased risk for multidrug-resistant (MDR) pathogens coming from community settings; such individuals would previously have been classified as having community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the definition of HCAP is being reevaluated since some authorities have argued that it is an overgeneralization to consider all HCAP patients at increased risk for MDR pathogens. The challenge for clinicians is to correctly identify the HCAP patient who is most likely to benefit from empiric treatment with broad-spectrum antibiotics with activity against MDR pathogens. The clinical issues surrounding HCAP are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H249925653#H249925653\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Approach to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The guidelines can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements/\">",
"     file://www.thoracic.org/statements/",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Multidrug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of multidrug resistance in gram-negative bacilli, which are an important cause of HAP, VAP, and HCAP, is variably defined as resistance to at least two, three, four, or eight of the antibiotics typically used to treat infections with these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pan-resistance refers to those gram-negative organisms with diminished susceptibility to all of the antibiotics recommended for the empiric treatment of VAP, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Empiric treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most significant risk factor for hospital-acquired pneumonia (HAP) is mechanical ventilation. In fact, many authors use the terms HAP and ventilator-associated pneumonia (VAP) interchangeably. Intubation increases the risk of pneumonia 6- to 21-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/1\">",
"     1",
"    </a>",
"    ]. Other risk factors, which have emerged from multivariate analyses, include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/5-15\">",
"     5-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;70 years",
"     </li>",
"     <li>",
"      Chronic lung disease",
"     </li>",
"     <li>",
"      Depressed consciousness",
"     </li>",
"     <li>",
"      Aspiration",
"     </li>",
"     <li>",
"      Chest surgery",
"     </li>",
"     <li>",
"      The presence of an intracranial pressure monitor or nasogastric tube",
"     </li>",
"     <li>",
"      H2 blocker or antacid therapy",
"     </li>",
"     <li>",
"      Transport from the intensive care unit (ICU) for diagnostic or therapeutic procedures",
"     </li>",
"     <li>",
"      Previous antibiotic exposure, particularly to third generation cephalosporins",
"     </li>",
"     <li>",
"      Reintubation or prolonged intubation",
"     </li>",
"     <li>",
"      Hospitalization during the fall or winter season",
"     </li>",
"     <li>",
"      Mechanical ventilation for acute respiratory distress syndrome",
"     </li>",
"     <li>",
"      Frequent ventilator circuit changes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=see_link\">",
"       \"The ventilator circuit and ventilator-associated pneumonia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paralytic agents",
"     </li>",
"     <li>",
"      Underlying illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of gastric pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have noted an increased incidence of HAP when the gastric pH is increased with the use of H2 blockers, antacids, or proton pump inhibitors (PPIs) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/6,16-19\">",
"     6,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial compared three strategies of stress ulcer prophylaxis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"      aluminum hydroxide",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/6/31847?source=see_link\">",
"      magnesium hydroxide",
"     </a>",
"    </span>",
"    antacid, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/17\">",
"     17",
"    </a>",
"    ]. The incidence of late-onset pneumonia (more than four days after intubation) was significantly lower with sucralfate compared with pH-altering drugs (5 versus 16 percent with antacids and 21 percent with ranitidine). Patients who received sucralfate had a lower median gastric pH and less frequent gastric colonization compared with the other groups. Nevertheless, when patients with pH &gt;4 were evaluated separately, the patients receiving sucralfate still exhibited lower rates of gastric colonization, suggesting that sucralfate may possess intrinsic antibacterial activity. There was a trend toward an increased incidence of gastric bleeding in patients taking sucralfate compared with antacids and ranitidine (10, 4, and 6 percent, respectively), but this difference was not statistically significant.",
"   </p>",
"   <p>",
"    In a large prospective cohort study of patients who were admitted to the hospital for &ge;3 days, the use of acid suppressive medication (PPIs or H2 blockers) was significantly associated with an increased risk of HAP (adjusted odds ratio [OR] 1.3, 95% CI 1.1-1.4 ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/18\">",
"     18",
"    </a>",
"    ]. In a subset analysis, the use of PPIs was significantly associated with an increased risk of HAP (adjusted OR 1.3, 95% CI 1.1-1.4). However, in contrast to the trial described above, the use of H2 blockers was not significantly associated with an increased risk of HAP (adjusted OR 1.2, 95% CI 0.98-1.4).",
"   </p>",
"   <p>",
"    In 2008, the Society of Healthcare Epidemiology and the Infectious Diseases Society of America recommended that H2 blockers and PPIs be avoided in patients who are not at high risk of developing a stress ulcer or stress gastritis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastric acid suppressive therapy with H2 blockers or PPIs appears to increase the risk of community-acquired pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\", section on 'Predisposing host conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, the Society of Healthcare Epidemiology and the Infectious Diseases Society of America (IDSA) issued practice recommendations to reduce the risk of ventilator-associated pneumonia (VAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition to minimizing mechanical ventilation, the recommendations included reducing colonization of the upper respiratory tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the digestive tract, as well as preventing aspiration (",
"    <a class=\"graphic graphic_table graphicRef69916 \" href=\"UTD.htm?42/30/43500\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among the various strategies that have been evaluated for preventing VAP, only decontamination of the oropharynx (with or without decontamination of the digestive tract) has been demonstrated to improve patient outcomes by preventing VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/20\">",
"     20",
"    </a>",
"    ]. This has primarily been demonstrated in settings of low antimicrobial resistance and may not apply to intensive care units with higher rates of resistance.",
"   </p>",
"   <p>",
"    The following discussion will review some of the modalities that are recommended. General issues related to infection control, such as hand hygiene and active surveillance, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Decontamination of the digestive tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decontamination of the digestive tract represents an attempt to reduce the incidence of pneumonia in critically ill patients by diminishing colonization of the upper respiratory tract. The methods used include antiseptics in the oropharynx and nonabsorbable antibiotics taken orally with or without systemic antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Decontamination of the oropharynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gingival and dental plaque rapidly becomes colonized with aerobic pathogens in intensive care unit (ICU) patients due to poor oral hygiene and lack of mechanical elimination. A number of trials have evaluated the efficacy of decontamination of the oropharynx.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis included 11 trials of 3242 mechanically ventilated adults who were treated with oral application of antibiotics or antiseptics or with placebo or standard oral care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/21\">",
"     21",
"    </a>",
"    ]. The incidence of VAP was significantly reduced by oral antiseptics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    (relative risk [RR] 0.56, 95% CI 0.39-0.81) but not oral applications of antibiotics (RR 0.69, 95% CI 0.41-1.18). Neither method of decontamination improved mortality.",
"   </p>",
"   <p>",
"    A subsequent randomized trial showed that decontamination of the oropharynx, using topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , resulted in a modest mortality benefit at day 28 on a post hoc analysis compared with no decontamination (absolute benefit 3.5 percent, adjusted odds ratio 0.86, 95% CI 0.74-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter open-label clustered group-randomized crossover study performed in the Netherlands included 5939 mechanically ventilated patients who received selective oropharyngeal decontamination, selective decontamination of the digestive tract (SDD), or standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/23\">",
"     23",
"    </a>",
"    ]. Significant reductions in bacteremia, bacteremia with highly resistant organisms, and respiratory colonization with highly resistant organisms were observed in patients who received selective oropharyngeal decontamination or SDD compared with those who received standard care. This is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Selective decontamination of the digestive tract'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Based upon the available data, we recommend performing regular oral care with an antiseptic solution in patients receiving mechanical ventilation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine",
"    </a>",
"    has been best studied. Although the optimal regimen has not been established, we suggest chlorhexidine 0.12% oral solution (15 mL twice daily until 24 hours after extubation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Selective decontamination of the digestive tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;SDD is a strategy that aims to decrease the incidence of VAP by preventing oropharyngeal and gastric colonization with aerobic gram-negative bacilli and Candida spp, without disrupting the anaerobic flora. A variety of regimens have been employed. Most use a combination of a locally administered nonabsorbable antibiotic (eg, polymyxin) and an aminoglycoside plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     nystatin",
"    </a>",
"    . The antibiotics are usually applied topically to the oropharynx or administered through a nasogastric tube. Some regimens include systemic antibiotics (most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ) in addition to nonabsorbable oral antibiotics.",
"   </p>",
"   <p>",
"    A limitation to the available data is that most studies relied on clinical criteria to diagnose pneumonia, which is known to be unreliable. As an example, a report evaluating the quality of these studies found an inverse relationship between methodologic quality scores and the incidence of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials and two meta-analyses suggest that SDD confers protection against pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 1998 meta-analysis included trials of critically ill patients who received topical plus systemic antibiotics versus no treatment OR topical antibiotics with or without a systemic antibiotic versus a systemic agent or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/25\">",
"       25",
"      </a>",
"      ]. Analysis of the 16 trials (3361 patients) that tested treatment with topical and systemic antibiotics showed a significant reduction in respiratory tract infection (odds ratio [OR] 0.35; 95% CI 0.29 to 0.41) and mortality (OR 0.80; CI 0.69 to 0.93). Analysis of 17 trials (2366 patients) that tested only topical antibiotics found a reduction in respiratory tract infection (OR 0.56; CI 0.46 to 0.68) but no reduction in mortality.",
"     </li>",
"     <li>",
"      A separate meta-analysis that focused on the impact of SDD on gram-negative and gram-positive carriage and infection found a lower rate of pneumonia due to both gram-negative and gram-positive bacteria, although the rate of oropharyngeal and rectal carriage was reduced only with gram-negative bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent randomized trial showed that SDD (four days of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , plus topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      in the oropharynx and stomach until ICU discharge) was associated with a modest mortality benefit at day 28 compared with no decontamination (adjusted OR 0.83, 95% CI 0.72-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/22\">",
"       22",
"      </a>",
"      ]. The benefit observed with SDD was similar to decontamination of the oropharynx compared with no decontamination (adjusted odds ratio 0.86, 95% CI 0.74-0.99), as described above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Decontamination of the oropharynx'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A multicenter open-label clustered group-randomized crossover study performed in the Netherlands (where the rates of antibiotic resistance are low) included 5939 mechanically ventilated patients who received standard care, SDD, or selective oropharyngeal decontamination [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/23\">",
"       23",
"      </a>",
"      ]. Among patients who received standard care, 13 percent developed bacteremia after three days compared with 7 percent of patients who received SDD (odds ratio [OR] 0.48, 95% CI 0.0.38-0.60) and 9 percent who received selective oropharyngeal decontamination (OR 0.66, 95% CI 0.53-0.82). Eight patients developed bacteremia with highly resistant organisms during SDD compared with 18 patients during standard care (OR 0.41, 95% CI 0.18-0.94) and 20 patients during selective oropharyngeal decontamination (OR 0.37, 95% OR 0.16-0.85). Among patients who stayed in the ICU for more than three days, 15 percent of patients who received standard care developed respiratory tract colonization with highly resistant organisms compared with 8 percent of patients who received SDD (OR 0.58, 95% CI 0.43-0.78) and 10 percent of patients who receiving selective oropharyngeal decontamination (OR 0.65, 95% CI 0.49-0.87).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the potential benefits described above, SDD has not found widespread favor in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/2\">",
"     2",
"    </a>",
"    ]. A major reason for this is concern about promoting the growth of resistant bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In addition, the applicability of the results of the trial described above to other settings has been questioned since very low rates of antibiotic resistance were present at the institutions included in the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Compared with North America, SDD is used more commonly in some countries in Europe, such as the Netherlands, where rates of resistant bacteria in intensive care units are substantially lower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3326221\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics are defined as live microorganisms of human origin that are able to tolerate the hostile gastrointestinal environment such that they persist in the lower alimentary tract to confer a health benefit to the host [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a randomized trial of 146 mechanically ventilated patients, the enteral administration of the probiotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    rhamnosus resulted in significantly lower rates of oropharyngeal and gastric bacterial colonization as well as subsequent VAP compared with placebo (19 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/32\">",
"     32",
"    </a>",
"    ]. The study was underpowered to demonstrate effects on mortality. No adverse events were observed among patients who received probiotic prophylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preventing aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration is a major predisposing mechanism for both hospital-acquired pneumonia (HAP) and VAP. Appropriate patient positioning and subglottic drainage in ventilated patients are two important modalities for the prevention of aspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supine positioning appears to predispose to aspiration and the development of HAP. Several studies have shown that patients in the supine position are predisposed to microaspiration of gastric contents as compared with patients in the semirecumbent position [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. A randomized trial of positioning in 90 intubated patients was stopped early when interim analysis found a significantly lower incidence of both clinically suspected and microbiologically confirmed HAP in semirecumbent versus supine patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/35\">",
"     35",
"    </a>",
"    ]. Although no effect of positioning on mortality has been demonstrated, it seems prudent to preferentially place intubated patients in the semirecumbent position unless contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Subglottic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drainage of subglottic secretions may lessen the risk of aspiration and thereby decrease the incidence of VAP. Specially designed endotracheal tubes have been developed to provide continuous or intermittent aspiration of subglottic secretions (",
"    <a class=\"graphic graphic_figure graphicRef68552 \" href=\"UTD.htm?36/5/36958\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ]. The same devices can also be used for intermittent aspiration of subglottic secretions.",
"   </p>",
"   <p>",
"    A meta-analysis of 13 randomized trials that included 2442 patients assessed the effect of subglottic secretion drainage on the prevention of VAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/38\">",
"     38",
"    </a>",
"    ]. Of the 13 trials, 12 reported a reduction in the VAP rates among patients who received aspiration of subglottic secretions; the overall risk ratio for VAP was 0.55 (95% CI 0.46-0.66). The use of aspiration of subglottic secretions was also associated with reduced length of ICU stay (-1.52 days, 95% CI -2.94 to -0.11 days), reduced duration of mechanical ventilation (-1.08 days, 95% CI -2.04 to -0.12 days), and increased time to first episode of VAP (2.66 days, 95% CI, 1.06-4.26 days). Despite these benefits, there was no effect on either ICU mortality or in-hospital mortality. Of the 13 studies, 5 used intermittent suction and the others continuous suction; reduction in VAP was similar for each method.",
"   </p>",
"   <p>",
"    The most extensively employed device is the Hi-Lo Evac (Mallinckrodt Inc; Athlone, Ireland); however, these tubes cost more than standard endotracheal tubes, and are not widely available. The potential economic impact of widespread use of subglottic secretion drainage is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4934851\">",
"    <span class=\"h3\">",
"     Gastric volume monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been standard clinical practice to monitor the patient's gastric residual volume at regular intervals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prior to increasing the infusion rate of gastric tube feeding, with the hope of minimizing the risk of unrecognized gastric fluid accumulation and vomiting resulting in pneumonia. However, several studies have shown that measurement of gastric residuals correlates poorly with aspiration risk and is associated with a decrease in calorie delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Furthermore, a randomized trial has shown that the rate of VAP was not higher in patients who did not undergo monitoring of gastric residuals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/43\">",
"     43",
"    </a>",
"    ]. Based on these findings, we do not routinely check gastric residual volumes in asymptomatic patients receiving tube feedings. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=see_link&amp;anchor=H25#H25\">",
"     \"Nutrition support in critically ill patients: Enteral nutrition\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Silver-coated endotracheal tube",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silver-coated endotracheal tubes (ETTs) reduce the incidence of VAP. This was illustrated in a prospective, randomized, single-blinded trial (NASCENT) in which a silver-coated ETT was compared with an uncoated ETT in 2003 patients requiring mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/44\">",
"     44",
"    </a>",
"    ]. Among patients intubated for more than 24 hours, the rate of microbiologically confirmed VAP was significantly lower with the silver-coated ETT (4.8 versus 7.5 percent). The silver-coated ETT was also associated with a significant delay in the occurrence of VAP. There were no differences between the groups in the duration of intubation, intensive care unit stay, or hospital stay; mortality; or the frequency or severity of adverse events.",
"   </p>",
"   <p>",
"    In a subsequent retrospective cohort analysis of patients enrolled in the NASCENT study, in patients with VAP, use of a silver-coated ETT was associated with reduced mortality compared with use of an uncoated ETT (14 versus 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/45\">",
"     45",
"    </a>",
"    ]. However, additional observations that were unexplained included a higher mortality in patients who used a silver-coated ETT who did not develop pneumonia, and a higher frequency of death from respiratory failure in those who used a silver-coated ETT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481536910\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress-dose glucocorticoids have been proposed as a possible method for preventing HAP in critically ill patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     Hydrocortisone",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for five days followed by 100 mg on day six and 50 mg on day seven) was compared with placebo in a multicenter trial that included 150 intubated patients with severe trauma requiring intensive care [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/46\">",
"     46",
"    </a>",
"    ]. The treatment was stopped in patients who had an appropriate adrenal response within the first 48 hours following inclusion. In the modified intention-to-treat analysis, patients who received hydrocortisone had a lower risk of HAP at 28 days compared with patients who received placebo (hazard ratio 0.47, 95% CI 0.25-0.86). Hydrocortisone use was also associated with a shorter duration of mechanical ventilation and a reduced risk of hyponatremia, but there was no difference in mortality compared with placebo.",
"   </p>",
"   <p>",
"    An accompanying editorial noted that this trial was not adequately powered to assess the effect of glucocorticoids on mortality, and that earlier trials have shown an increase in mortality in patients with traumatic brain injury (TBI) or persistent acute respiratory distress syndrome (ARDS) and mixed results regarding the effect on HAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In patients with TBI, administration of glucocorticoids was not associated with a reduced rate of HAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/48\">",
"     48",
"    </a>",
"    ], whereas in patients with ARDS, administration of glucocorticoids was associated with lower rates of suspected or probable HAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/49\">",
"     49",
"    </a>",
"    ]. Further studies are necessary to more clearly define the potential benefits and safety of glucocorticoid use in these populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of glucocorticoids in patients with septic shock and ARDS is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=see_link&amp;anchor=H16#H16\">",
"     \"Novel therapies for the acute respiratory distress syndrome\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76306450\">",
"    <span class=\"h2\">",
"     Prevention bundles",
"    </span>",
"    &nbsp;&mdash;&nbsp;VAP prevention bundles involve the implementation of various measures in an attempt to reduce the incidence of VAP among patients at risk. Such measures often include educational programs, technical measures, surveillance, and feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/50\">",
"     50",
"    </a>",
"    ]. In one study, eight practices were chosen to prevent VAP: hand hygiene, glove and gown compliance, elevation of the head of the bed, oral care with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , maintaining an endotracheal tube cuff pressure &gt;20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0, orogastric rather than nasogastric feeding tubes, avoiding gastric overdistention, and eliminating nonessential tracheal suctioning [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/50\">",
"     50",
"    </a>",
"    ]. After institution of the prevention bundle, the rate of VAP decreased from 23 to 13 VAP episodes per 1000 ventilator-days. Despite the observed reduction in the incidence of VAP as defined in the study, there were no differences in the total duration of mechanical ventilation or the ICU and hospital death rates.",
"   </p>",
"   <p>",
"    Although the results are promising, limitations of this study include the lack of inclusion of certain measures in the bundle (eg, digestive tract decontamination, daily sedative interruption, daily assessment of readiness to extubate, silver-coated endotracheal tubes, continuous aspiration of subglottic secretions) and suboptimal adherence with hand hygiene and elevation of the head of the bed; the inclusion of or adherence to these measures might have resulted in an even greater benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/51\">",
"     51",
"    </a>",
"    ]. Another important issue is that the surveillance definition of VAP is not sufficiently objective to provide confidence that the rate of reduction of VAP reported in this study and other studies is accurate.",
"    <br/>",
"    <br/>",
"    Another proposed bundle includes five interventions: semirecumbent position, stress ulcer prophylaxis, deep vein thrombosis prophylaxis, adjustment of sedation so that the patient can follow commands, and daily assessment for extubation. This bundle was tested in 112 ICUs with 550,800 ventilator-days and showed that the VAP rate decreased from a median of 5.5 cases per 1000 ventilator-days at baseline to a median of 0 cases at 16 to 18 months after implementation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13433/abstract/52\">",
"     52",
"    </a>",
"    ]. A limitation of this study is its observational design; it was a cohort study that compared the rates before and after implementing the intervention, rather than evaluating the effect of the bundle in a randomized controlled trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/1/19474?source=see_link\">",
"       \"Patient information: Hospital-acquired pneumonia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following types of nosocomial pneumonia have been defined:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hospital-acquired pneumonia (HAP) is pneumonia that occurs 48 hours or more after admission, and did not appear to be incubating at the time of admission.",
"     </li>",
"     <li>",
"      Ventilator-associated pneumonia (VAP) is a type of HAP that develops more than 48 to 72 hours after endotracheal intubation.",
"     </li>",
"     <li>",
"      Healthcare-associated pneumonia (HCAP) includes any patient who was either hospitalized in an acute care hospital for two or more days within 90 days of the infection; or resided in a long term care facility; or received intravenous antimicrobial therapy, chemotherapy, or wound care within the 30 days prior to the current infection; or attends a hospital or hemodialysis clinic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multidrug resistance in gram-negative bacilli, which are an important cause of HAP, VAP, and HCAP, is variably defined as resistance to at least two, three, four, or eight of the antibiotics typically used to treat infections with these organisms (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The most significant risk factor for HAP is mechanical ventilation; other significant risk factors include age &gt;70 years, chronic lung disease, depressed consciousness, and aspiration, among others. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive measures include avoidance of acid-blocking medications, decontamination of the oropharynx, patient positioning, and subglottic drainage. In 2008, the Society of Healthcare Epidemiology and the Infectious Diseases Society of America (IDSA) issued practice recommendations to reduce the risk of VAP. In addition to minimizing mechanical ventilation, the recommendations included reducing colonization of the aerodigestive tract and preventing aspiration (",
"      <a class=\"graphic graphic_table graphicRef69916 \" href=\"UTD.htm?42/30/43500\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/1\">",
"      Guideline for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. Respir Care 1994; 39:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/2\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/3\">",
"      Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/4\">",
"      Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/5\">",
"      Craven DE, Kunches LM, Kilinsky V, et al. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986; 133:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/6\">",
"      Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004; 32:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/7\">",
"      Bornstain C, Azoulay E, De Lassence A, et al. Sedation, sucralfate, and antibiotic use are potential means for protection against early-onset ventilator-associated pneumonia. Clin Infect Dis 2004; 38:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/8\">",
"      Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988; 93:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/9\">",
"      Kollef MH, Von Harz B, Prentice D, et al. Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia. Chest 1997; 112:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/10\">",
"      Torres A, Gatell JM, Aznar E, et al. Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Am J Respir Crit Care Med 1995; 152:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/11\">",
"      Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993; 270:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/12\">",
"      Kollef MH, Vlasnik J, Sharpless L, et al. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/13\">",
"      Chastre J, Trouillet JL, Vuagnat A, et al. Nosocomial pneumonia in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/14\">",
"      Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/15\">",
"      Hortal J, Giannella M, P&eacute;rez MJ, et al. Incidence and risk factors for ventilator-associated pneumonia after major heart surgery. Intensive Care Med 2009; 35:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/16\">",
"      Collard HR, Saint S, Matthay MA. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med 2003; 138:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/17\">",
"      Prod'hom G, Leuenberger P, Koerfer J, et al. Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994; 120:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/18\">",
"      Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009; 301:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/19\">",
"      Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011; 183:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/20\">",
"      Bonten MJ. Healthcare epidemiology: Ventilator-associated pneumonia: preventing the inevitable. Clin Infect Dis 2011; 52:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/21\">",
"      Chan EY, Ruest A, Meade MO, Cook DJ. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ 2007; 334:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/22\">",
"      de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/23\">",
"      de Smet AM, Kluytmans JA, Blok HE, et al. Selective digestive tract decontamination and selective oropharyngeal decontamination and antibiotic resistance in patients in intensive-care units: an open-label, clustered group-randomised, crossover study. Lancet Infect Dis 2011; 11:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/24\">",
"      van Nieuwenhoven CA, Buskens E, van Tiel FH, Bonten MJ. Relationship between methodological trial quality and the effects of selective digestive decontamination on pneumonia and mortality in critically ill patients. JAMA 2001; 286:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/25\">",
"      D'Amico R, Pifferi S, Leonetti C, et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ 1998; 316:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/26\">",
"      S&aacute;nchez Garc&iacute;a M, Cambronero Galache JA, L&oacute;pez Diaz J, et al. Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients. A randomized, double-blind, placebo-controlled, multicenter trial. Am J Respir Crit Care Med 1998; 158:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/27\">",
"      de Jonge E, Schultz MJ, Spanjaard L, et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial. Lancet 2003; 362:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/28\">",
"      Silvestri L, van Saene HK, Casarin A, et al. Impact of selective decontamination of the digestive tract on carriage and infection due to Gram-negative and Gram-positive bacteria: a systematic review of randomised controlled trials. Anaesth Intensive Care 2008; 36:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/29\">",
"      Wunderink RG. Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract. Am J Respir Crit Care Med 2010; 181:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/30\">",
"      Oostdijk EA, de Smet AM, Blok HE, et al. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 2010; 181:452.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Agriculture Organization of the United Nations and World Health Organization. Guidelines for the evaluation of probiotics in food. file://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf (Accessed on January 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/32\">",
"      Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010; 182:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/33\">",
"      Torres A, Serra-Batlles J, Ros E, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992; 116:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/34\">",
"      Orozco-Levi M, Torres A, Ferrer M, et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med 1995; 152:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/35\">",
"      Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999; 354:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/36\">",
"      Smulders K, van der Hoeven H, Weers-Pothoff I, Vandenbroucke-Grauls C. A randomized clinical trial of intermittent subglottic secretion drainage in patients receiving mechanical ventilation. Chest 2002; 121:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/37\">",
"      Kollef MH, Skubas NJ, Sundt TM. A randomized clinical trial of continuous aspiration of subglottic secretions in cardiac surgery patients. Chest 1999; 116:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/38\">",
"      Muscedere J, Rewa O, McKechnie K, et al. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med 2011; 39:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/39\">",
"      Shorr AF, O'Malley PG. Continuous subglottic suctioning for the prevention of ventilator-associated pneumonia : potential economic implications. Chest 2001; 119:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/40\">",
"      Mentec H, Dupont H, Bocchetti M, et al. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med 2001; 29:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/41\">",
"      McClave SA, Lukan JK, Stefater JA, et al. Poor validity of residual volumes as a marker for risk of aspiration in critically ill patients. Crit Care Med 2005; 33:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/42\">",
"      Montejo JC, Mi&ntilde;ambres E, Bordej&eacute; L, et al. Gastric residual volume during enteral nutrition in ICU patients: the REGANE study. Intensive Care Med 2010; 36:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/43\">",
"      Reignier J, Mercier E, Le Gouge A, et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. JAMA 2013; 309:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/44\">",
"      Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008; 300:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/45\">",
"      Afessa B, Shorr AF, Anzueto AR, et al. Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest 2010; 137:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/46\">",
"      Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011; 305:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/47\">",
"      Bulger EM, Cuschieri J. Steroids after severe injury: many unanswered questions. JAMA 2011; 305:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/48\">",
"      Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet 2004; 364:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/49\">",
"      Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/50\">",
"      Bouadma L, Deslandes E, Lolom I, et al. Long-term impact of a multifaceted prevention program on ventilator-associated pneumonia in a medical intensive care unit. Clin Infect Dis 2010; 51:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/51\">",
"      Klompas M. Ventilator-associated pneumonia: is zero possible? Clin Infect Dis 2010; 51:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13433/abstract/52\">",
"      Berenholtz SM, Pham JC, Thompson DA, et al. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol 2011; 32:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6995 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13433=[""].join("\n");
var outline_f13_7_13433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pneumonia types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Multidrug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of gastric pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Decontamination of the digestive tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Decontamination of the oropharynx",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Selective decontamination of the digestive tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3326221\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preventing aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Subglottic drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4934851\">",
"      - Gastric volume monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Silver-coated endotracheal tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H481536910\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76306450\">",
"      Prevention bundles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6995\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6995|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/5/36958\" title=\"figure 1\">",
"      Continuous aspiration system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6995|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/30/43500\" title=\"table 1\">",
"      Strategies prevent VAP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24040?source=related_link\">",
"      Clinical presentation and diagnosis of ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34073?source=related_link\">",
"      Nutrition support in critically ill patients: Enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/1/19474?source=related_link\">",
"      Patient information: Hospital-acquired pneumonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6695?source=related_link\">",
"      The ventilator circuit and ventilator-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_7_13434="Management of hypertension in pregnant and postpartum women";
var content_f13_7_13434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of hypertension in pregnant and postpartum women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13434/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13434/contributors\">",
"     Phyllis August, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13434/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13434/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13434/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/7/13434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/7/13434/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/7/13434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H198338085\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major hypertensive disorders that occur in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preeclampsia-eclampsia",
"      </strong>",
"      &mdash; Preeclampsia refers to the syndrome of new onset of hypertension and proteinuria most often after 20 weeks of gestation in a previously normotensive woman (",
"      <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"       table 1",
"      </a>",
"      ). It is important to recognize that there is heterogeneity in the presentation; some women with preeclampsia may manifest additional features such as elevated liver enzymes and low platelet count (HELLP syndrome). Eclampsia is diagnosed when seizures have occurred. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Chronic (preexisting) hypertension",
"      </strong>",
"      &mdash; Chronic hypertension is defined as systolic pressure &ge;140 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic pressure &ge;90 mmHg that antedates pregnancy, is present before the 20th week of pregnancy, or persists longer than 12 weeks postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Preeclampsia-eclampsia superimposed upon chronic hypertension",
"      </strong>",
"      &mdash; Preeclampsia-eclampsia superimposed upon chronic hypertension is diagnosed when a woman with chronic hypertension develops worsening hypertension with new onset proteinuria or other features of preeclampsia (eg, elevated liver enzymes, low platelet count).",
"     </li>",
"     <li>",
"      <strong>",
"       Gestational hypertension",
"      </strong>",
"      &mdash; Gestational hypertension refers to elevated blood pressure first detected after 20 weeks of gestation in the absence of proteinuria or other diagnostic features of preeclampsia (",
"      <a class=\"graphic graphic_table graphicRef56709 \" href=\"UTD.htm?0/37/603\">",
"       table 2",
"      </a>",
"      ). Over time, some patients with gestational hypertension will develop proteinuria and be considered preeclamptic, while others will be diagnosed with preexisting hypertension because of persistent blood pressure elevation postpartum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss the treatment of hypertension related to these disorders in pregnant and postpartum women. Other aspects of these disorders are reviewed in separate topics, including, but not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"       \"Preeclampsia: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link\">",
"       \"Eclampsia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"       \"Gestational hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53704432\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to treat hypertension during pregnancy should consider the risks and benefits for both mother and fetus. The level of blood pressure is the most important factor, as treatment of severe hypertension (systolic BP &ge;160 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic BP &ge;110 mmHg) has a well-established maternal benefit of reduction in stroke risk. However, additional factors should also be considered. The underlying etiology of the elevated blood pressure may be relevant; for example, women with chronic hypertension may tolerate higher blood pressures better than previously normotensive women with acute hypertension due to preeclampsia. Timing of delivery is also a factor; if prompt cesarean delivery is planned, antihypertensive therapy may not be needed as anesthesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    may lower blood pressure.",
"   </p>",
"   <p>",
"    The decision to use antihypertensive therapy in women with mild (140 to 150 mmHg systolic, 90 to 100 mmHg diastolic) to moderate (systolic 150 to 159 mmHg, diastolic 100 to 109 mmHg) hypertension is less clear. Maternal or fetal benefits from treatment of mild to moderate hypertension over the relatively short duration of a full term pregnancy have not been demonstrated and there is evidence that, in some women, aggressive lowering of blood pressure, or even the medications themselves, can inhibit fetal growth and expose the fetus to potentially harmful physiological effects of these drugs. These conclusions are supported by the following lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2002 meta-analysis that specifically evaluated the effect of lowering maternal blood pressure on fetal weight, fetal growth was significantly impaired by the reduction in mean arterial pressure induced by antihypertensive therapy: a 10 mmHg fall in mean arterial pressure was associated with a 176 gram decrease in birth weight [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/2\">",
"       2",
"      </a>",
"      ]. This effect was unrelated to the type of hypertension or choice of medication.",
"     </li>",
"     <li>",
"      In a 2007 meta-analysis that evaluated maternal and fetal outcomes in randomized trials of treatment versus no treatment of pregnant women with mild to moderate hypertension, treatment did not result in either fetal benefit or harm (mild to moderate hypertension was defined as 140 to",
"      <span class=\"nowrap\">",
"       169/90",
"      </span>",
"      to 109 mmHg related to any diagnostic category of pregnancy hypertension) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/3\">",
"       3",
"      </a>",
"      ]. Although antihypertensive therapy significantly decreased the incidence of severe hypertension by one-half to two-thirds and the need for additional antihypertensive drugs by almost two-thirds, it did not affect perinatal mortality or the frequency of prematurity, preeclampsia, delivery of a small for gestational age infant, or abruptio placentae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this evidence is helpful, there are gaps in information and most clinical trials have included small numbers of patients who have a variety of diagnoses.",
"   </p>",
"   <p>",
"    Therefore, a prudent approach should also consider the patient&rsquo;s comorbidities and symptoms (eg, headaches, visual disturbances) when deciding whether to treat mild to moderate hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705179\">",
"    <span class=\"h2\">",
"     Antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All antihypertensive drugs cross the placenta. There are no data from large well-designed randomized trials on which to base a recommendation for use of one drug over another. Data regarding both comparative efficacy in improving pregnancy outcome and fetal safety are inadequate for almost all antihypertensive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705301\">",
"    <span class=\"h3\">",
"     Options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following drugs are effective antihypertensive agents with an acceptable safety profile in pregnancy. The choice of drug depends on the acuity and severity of hypertension and whether or not parental or oral therapy is used; these factors are discussed below. (See",
"    <a class=\"local\" href=\"#H53706253\">",
"     'Management of common hypertensive disorders during pregnancy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705507\">",
"    <span class=\"h4\">",
"     Methyldopa",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     Methyldopa",
"    </a>",
"    has been widely used in pregnant women and its long-term safety for the fetus has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/4\">",
"     4",
"    </a>",
"    ], but it is only a mild antihypertensive agent and has a slow onset of action (three to six hours). Many women will not achieve blood pressure goals on this oral agent or are bothered by its sedative effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705068\">",
"    <span class=\"h4\">",
"     Beta-blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    has both alpha- and beta-adrenergic blocking activity, and may preserve uteroplacental blood flow to a greater extent than traditional beta-blockers. It has a more rapid onset of action than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    (within two hours versus three to six hours). Randomized trials comparing labetalol to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    or methyldopa have shown that labetalol is effective and generally safe in pregnancy, although data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. It may be administered orally or parenterally. Although less well studied in pregnant women,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    and the long-acting form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    are acceptable alternative agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of other beta-adrenergic blockers, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , is somewhat controversial due to individual reports of premature labor and neonatal apnea, fetal growth restriction, bradycardia, and hypoglycemia. Furthermore, myometrial relaxation of the gravid uterus is a beta2-receptor-mediated process, and nonselective beta-adrenergic blockers (such as propranolol) may counteract the effect of beta2 stimulation. Beta-adrenergic blockers that lack alpha-blocking properties (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    ) have been associated with lower placental and fetal weight at delivery when used early in pregnancy, and are generally avoided if an effective drug with a better safety profile is available [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705077\">",
"    <span class=\"h4\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers appear to be safe for use in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/9\">",
"     9",
"    </a>",
"    ]. Long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (30 to 90 mg once daily as sustained release tablet, increase at 7- to 14-day intervals, maximum dose 120",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    has been used without major problems [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/10\">",
"     10",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    is widely used in non-pregnant individuals with hypertension, there are sparse data of its use in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/11\">",
"     11",
"    </a>",
"    ]. Nondihydropyridine calcium antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    have been used, as well, although most reports in the literature are of small numbers of women. We do not use immediate release nifedipine, either orally or sublingually, for treatment of hypertension because it may cause significant, rapid decreases in blood pressure. Use of immediate onset nifedipine has been associated with adverse outcomes such as stroke and myocardial infarction in older, nonpregnant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29869708\">",
"    <span class=\"h4\">",
"     Hydralazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    has been used extensively in the setting of preeclampsia for the acute treatment of severe hypertension. Although a meta-analysis demonstrated a slightly increased rate of adverse events with hydralazine compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    , the evidence was not sufficient to make a definitive recommendation for one drug over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/12\">",
"     12",
"    </a>",
"    ]. Hydralazine has been widely used for many years in the setting of acute hypertension in pregnancy and is an acceptable antihypertensive drug in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. However, the hypotensive response to hydralazine is less predictable than that seen with other parenteral agents. Hydralazine can also be taken orally; however, it causes reflex tachycardia and fluid retention, which limit its usefulness in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705086\">",
"    <span class=\"h4\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of thiazide diuretics has been a source of controversy, although some guidelines suggest that these agents can be continued in women with chronic hypertension who were taking them prior to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Significant volume depletion is not likely in this setting, since all of the fluid loss occurs within the first two weeks of use, assuming that drug dose and dietary sodium intake are relatively constant. Diuretics are not generally used in women with preeclampsia unless pulmonary edema has developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53704941\">",
"    <span class=\"h3\">",
"     Drugs to avoid in pregnancy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705356\">",
"    <span class=\"h4\">",
"     ACE inhibitors, ARBs, direct renin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and direct renin inhibitors are contraindicated at all stages of pregnancy because they are associated with significant fetal renal abnormalities when maternal exposure has been in the latter half of pregnancy, and first trimester exposure has been associated with fetal cardiac abnormalities. Therefore, it is best to avoid initiating these drugs during pregnancy and to discontinue these agents in women planning pregnancy and switch to another agent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705365\">",
"    <span class=\"h4\">",
"     Nitroprusside",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     Nitroprusside",
"    </a>",
"    is contraindicated in the later stages of pregnancy due to possible fetal cyanide poisoning if used for more than four hours. However, nitroprusside (0.5 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg/min)",
"    </span>",
"    is the agent of last resort for urgent control of refractory severe hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53705226\">",
"    <span class=\"h3\">",
"     Options for breastfeeding mothers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding does not increase blood pressure in nursing mothers. Beta-adrenergic blockers and calcium channel blockers enter breast milk; however, most appear to be safe during lactation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/18\">",
"     18",
"    </a>",
"    ] and are considered \"compatible\" with breastfeeding by experts (see individual drugs in the drug database). It is prudent to consult with the infant&rsquo;s pediatrician before initiating maternal antihypertensive drugs.",
"   </p>",
"   <p>",
"    Within each class of antihypertensive agents, physicians should select the medication with the lowest transfer into human milk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Beta-blockers and",
"       <span class=\"nowrap\">",
"        alpha/beta-blockers",
"       </span>",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      have the lowest transfer into milk, with relative infant doses of less than 2 percent. None has been associated with adverse events in infants.",
"      <br/>",
"      <br/>",
"      In contrast, case reports have implicated both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/11/37047?source=see_link\">",
"       acebutolol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/19\">",
"       19",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/20\">",
"       20",
"      </a>",
"      ] in beta-blockade in nursing infants. These drugs should be avoided in breastfeeding mothers, if possible; if used, the infant should be observed for signs of beta-blockade.",
"      <br/>",
"      <br/>",
"      There are no human data on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      , but transfer into milk in rats is low (&lt;2 percent). There are no human data on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , but because of its low molecular weight, it is likely to be excreted into breast milk.",
"     </li>",
"     <li>",
"      <strong>",
"       Calcium channel blockers",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       Diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      are associated with a relative infant dose of less than 2 percent. The American Academy of Pediatrics (AAP) lists all three as compatible with breastfeeding.",
"     </li>",
"     <li>",
"      <strong>",
"       Angiotensin converting enzyme (ACE) inhibitors",
"      </strong>",
"      &mdash; These drugs are transferred into milk at very low levels.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"       Captopril",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      have been reviewed by the AAP and are compatible for use in lactation. However, newborns may be more susceptible to the hemodynamic effects of these drugs, such as hypotension, and sequelae such as oliguria and seizures. Therefore, we suggest that the hemodynamic status of the infant be taken into account when deciding whether women taking these drugs should breastfeed.",
"      <br/>",
"      <br/>",
"      There is no information on use of angiotensin II receptor blockers during breastfeeding.",
"     </li>",
"     <li>",
"      <strong>",
"       Diuretics",
"      </strong>",
"      &mdash; Theoretically, diuretics may reduce milk volume, but the AAP considers their use compatible with breastfeeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198338096\">",
"    <span class=\"h2\">",
"     Activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not advise bedrest for most pregnant women with hypertension, particularly those with stable chronic hypertension. Restricted activity is disruptive for most women and can be associated with deconditioning, bone loss, and possibly an increased risk of thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/21\">",
"     21",
"    </a>",
"    ]. Reduced activity (including bed rest) for women with preeclampsia may improve uteroplacental blood flow and prevent exacerbation of hypertension, particularly if blood pressure is not adequately controlled; however, there is no evidence that it significantly improves major maternal or fetal outcomes. Recommendations for level of activity should be individualized; for example, a woman with stable chronic hypertension early in pregnancy is unlikely to benefit from bedrest, while a woman with newly diagnosed preeclampsia in the third trimester should be advised to limit activity if she is being managed as an outpatient.",
"   </p>",
"   <p>",
"    There are no large randomized trials that have evaluated the benefits and risks of bedrest in the management of pregnant women with hypertension of any etiology. A 2005 Cochrane review of bedrest during pregnancy for management of hypertension included only four trials with a total of 449 women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/22\">",
"     22",
"    </a>",
"    ]. Two trials (145 women) compared strict bedrest with some rest in hospital for women with proteinuric hypertension and did not find any differences in outcome between the groups. The other two trials (304 women) compared some bedrest in hospital with routine activity at home for women with nonproteinuric hypertension and reported some bedrest was associated with a reduced risk of severe hypertension (1 trial, 218 women; RR 0.58, 95% CI 0.38-0.89) and a borderline reduction in risk of preterm birth (1 trial, 218 women; RR 0.53, 95% CI 0.29-0.99).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53710442\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal diet without significant salt restriction is generally advised, as salt restriction may induce low intravascular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53706253\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMMON HYPERTENSIVE DISORDERS DURING PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive treatment of preeclampsia is delivery, which is always beneficial for the mother. As long as the gravida remains undelivered, she is at increased risk of complications such as seizures, abruption, thrombocytopenia, cerebral hemorrhage, pulmonary edema, liver hemorrhage, and acute kidney injury. The risk of these complications subsides in the hours after delivery since preeclampsia is a completely reversible disease process. However, delivery may not be beneficial for the fetus if it is born preterm. Although the fetus is at increased risk of intrauterine growth restriction and stillbirth in the preeclamptic environment, conservative management, including antihypertensive therapy, may be pursued in selected cases to gain fetal maturity.",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and overall management of preeclampsia are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Indications for antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not prescribe antihypertensive therapy for mild hypertension, which we define as blood pressures consistently less than",
"    <span class=\"nowrap\">",
"     150/100",
"    </span>",
"    mmHg. The only benefit that has been demonstrated so far of antihypertensive therapy in pregnant women with mild hypertension is a reduction in risk of developing severe hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/3\">",
"     3",
"    </a>",
"    ], which we consider insufficient to warrant exposing the fetus to the potential adverse effects from these drugs (see",
"    <a class=\"local\" href=\"#H53704432\">",
"     'General approach'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/2\">",
"     2",
"    </a>",
"    ]. Lowering blood pressure does not affect the course of preeclampsia because the primary pathogenetic process is an abnormality of the placental vasculature that results in placental underperfusion, which, in turn, leads to release of factors that cause widespread maternal endothelial dysfunction with multiorgan dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe hypertension should be treated to prevent maternal vascular complications (eg, stroke, heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1\">",
"     1",
"    </a>",
"    ]. There is no consensus as to the optimal blood pressure threshold for initiating therapy. We initiate antihypertensive therapy in adult women at systolic pressures &ge;150 mmHg or diastolic blood pressures &ge;100 mmHg. We may initiate treatment earlier in women with signs of cardiac decompensation or cerebral symptoms (eg, severe headache, visual disturbances, chest discomfort, shortness of breath, confusion) and in younger women whose baseline blood pressures were low (less than",
"    <span class=\"nowrap\">",
"     90/75",
"    </span>",
"    mmHg), but we acknowledge that this recommendation is not strongly evidence based.",
"   </p>",
"   <p>",
"    Other physicians begin antihypertensive treatment when systolic pressure is &ge;160 mmHg or diastolic pressure is &ge;105 to 110 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. However, in an analysis of 24 women with stroke related to preeclampsia, 4 percent had systolic blood pressures &gt;155 mmHg and &lt;160 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High quality clinical trials are needed to clarify the parameters for antihypertensive use in women with preeclampsia. At present, there is a lack of high quality evidence to support practice recommendations because the available trials are limited by several factors, including differences in blood pressure measurement techniques, diagnostic criteria, etiology of hypertension, and target blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Choice of drug and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two settings in which antihypertensive therapy is used in preeclampsia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute management of severe hypertension, which may require parenteral therapy, and",
"     </li>",
"     <li>",
"      Longer-term blood pressure control during expectant management of severe preeclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1,5\">",
"       1,5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"       \"Expectant management of severe preeclampsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    are the best options for first-line therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       Labetalol",
"      </a>",
"      &mdash; We recommend intravenous labetalol for first-line therapy because it is effective, has a rapid onset of action, and a good safety profile.",
"      <br/>",
"      <br/>",
"      Begin with 20 mg intravenously over 2 minutes followed at 10-minute intervals by doses of 20 to 80 mg up to a maximum total cumulative dose of 300 mg. As an example, give 20 mg, then 40 mg, then 80 mg, then 80 mg, then 80 mg. A constant infusion of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/min",
"      </span>",
"      can be used instead of intermittent therapy. The fall in blood pressure begins within 5 to 10 minutes and lasts from 3 to 6 hours. Continuous cardiac monitoring is not necessary routinely, but should be used in patients with relevant co-morbidities (eg, coronary artery disease).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       Hydralazine",
"      </a>",
"      &mdash; Begin with 5 mg intravenously over 1 to 2 minutes; if the blood pressure goal is not achieved within 20 minutes, give a 5 to 10 mg bolus depending upon the initial response. The maximum bolus dose is 20 mg. If a total dose of 30 mg does not achieve optimal blood pressure control, another agent should be used. The fall in blood pressure begins within 10 to 30 minutes and lasts from 2 to 4 hours.",
"     </li>",
"     <li>",
"      <strong>",
"       Calcium channel blockers",
"      </strong>",
"      &mdash; Sustained release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (30 mg) and immediate release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      are other options. Nicardipine can be given intravenously. Experience with these drugs in pregnancy is more limited than for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ; however, published experience showed that target blood pressure was reached within 23 minutes in 70 percent of pregnant patients with severe hypertension and 91 percent reached target blood pressure within 130 minutes, with no severe maternal or fetal side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/25\">",
"       25",
"      </a>",
"      ]. A more complete review of drug doses and potential side effects is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link\">",
"       \"Drug treatment of hypertensive emergencies\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We do not use immediate release nifedipine, either orally or sublingually, for treatment of hypertension because of the risk of acute, precipitous falls in blood pressure, which have been associated with serious cardiovascular morbidity (eg, stroke, myocardial infarction) in older, nonpregnant patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       Nitroglycerin",
"      </a>",
"      <strong>",
"      </strong>",
"      &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       Nitroglycerin (glyceryl trinitrate)",
"      </a>",
"      is a good option for treatment of hypertension associated with pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/23\">",
"       23",
"      </a>",
"      ]. It is given as an intravenous infusion of 5",
"      <span class=\"nowrap\">",
"       mcg/min",
"      </span>",
"      and gradually increased every 3 to 5 minutes to a maximum dose of 100",
"      <span class=\"nowrap\">",
"       mcg/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Long-term oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, preeclamptic women with severe hypertension remote from term are stabilized and not delivered immediately. Oral antihypertensive therapy is often indicated for these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"     \"Expectant management of severe preeclampsia\"",
"    </a>",
"    .) Options for oral antihypertensive therapy are the same as for women with preexisting hypertension (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Choice of drug'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Target blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our target blood pressures are 130 to 150 mm Hg systolic and 80 to 100 mm Hg diastolic. The rapidity with which blood pressure should be brought to safe levels is controversial. Cerebral or myocardial ischemia or infarction can be induced by aggressive antihypertensive therapy if the blood pressure falls below the range at which tissue perfusion can be maintained by autoregulation. Therefore, reducing mean arterial pressure by no more than 25 percent over 2 hours and achieving a target of 130 to 150 mmHg systolic and 80 to 100 mmHg diastolic seems reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/26\">",
"     26",
"    </a>",
"    ]. We acknowledge the lack of clinical trial data to support these recommendations, and the need to individualize therapy based upon maternal and fetal factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=see_link\">",
"     \"Management of severe asymptomatic hypertension (hypertensive urgencies)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gestational hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for and choice of antihypertensive therapy in women with gestational hypertension are the same as for women with preeclampsia. The clinical features, evaluation, and overall management of these patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"     \"Gestational hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic (preexistent) hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension with or without antihypertensive drug treatment is associated with adverse pregnancy outcome (eg, poor fetal growth, stillbirth, iatrogenic preterm birth) and accounts for a substantial fraction of maternal morbidity (eg, pulmonary edema, stroke) compared with normotensive pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/27\">",
"     27",
"    </a>",
"    ]. However, most pregnancy outcome studies have not distinguished between women with chronic hypertension alone versus those with chronic hypertension and superimposed preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of adverse pregnancy outcome increases with the severity of hypertension and presence of end-organ damage. The absolute ranges of risk for adverse pregnancy outcomes reported in observational studies of women with",
"    <strong>",
"     mild",
"    </strong>",
"    preexisting hypertension are [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superimposed preeclampsia &mdash; 10 to 25 percent (versus 3 to 5 percent in the general obstetrical population)",
"     </li>",
"     <li>",
"      Abruptio placentae &mdash; 0.7 to 1.5 percent (versus &le;1 percent in the general obstetrical population)",
"     </li>",
"     <li>",
"      Fetal growth restriction &mdash; 8 to 16 percent (versus 10 percent in the general obstetrical population)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These risks were even higher in women with",
"    <strong>",
"     severe",
"    </strong>",
"    preexisting hypertension in the first trimester, and were highest for those with both severe hypertension and superimposed preeclampsia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superimposed preeclampsia &mdash; 50 percent",
"     </li>",
"     <li>",
"      Abruptio placenta &mdash; 5 to 10 percent",
"     </li>",
"     <li>",
"      Preterm birth &mdash; 62 to 70 percent",
"     </li>",
"     <li>",
"      Fetal growth restriction &mdash; 31 to 40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Superimposed preeclampsia, abruptio placentae, and fetal growth restriction are common reasons for iatrogenic preterm delivery. Twelve to 34 percent of women with mild preexistent hypertension deliver preterm, often for these indications and often requiring cesarean birth [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these risks, the treatment of preexisting hypertension during pregnancy is controversial. Beneficial effects of treatment appear to be limited to prevention of maternal morbidity and depend upon the severity of the disease (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Indications for treatment'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Maternal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the hypertensive patient is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=see_link\">",
"     \"Initial evaluation of the hypertensive adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although uncommon, nonobese women under age 30 years with a confirmed negative family history of hypertension may have secondary hypertension, so causes of secondary hypertension should be considered in those with suggestive clinical features such as severe or resistant hypertension, acute onset of hypertension, or proven onset of hypertension before puberty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Baseline laboratory tests that have been recommended for pregnant women with hypertension include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Urine culture",
"     </li>",
"     <li>",
"      Creatinine",
"     </li>",
"     <li>",
"      Glucose",
"     </li>",
"     <li>",
"      Electrolytes",
"     </li>",
"     <li>",
"      Quantitative analysis of urine protein &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tests will effectively screen for the presence of renal disease, and will also identify important comorbidities, such as diabetes mellitus. Women with proteinuria on a urine dipstick or urinalysis should have a quantitative test for 24-hour urine protein excretion. An electrocardiogram should be obtained in women with long-standing hypertension. Measurement of serum uric acid and liver enzymes is also reasonable in order to establish baseline levels, since these tests are often used in the evaluation of preeclampsia. Since both hypo- and hyper-thyroidism may be associated with hypertension, it is reasonable to assess thyroid function, although values should be interpreted with caution since alterations in thyroid-stimulating hormone (TSH) and thyroid hormone levels are not unusual, especially in early pregnancy.",
"   </p>",
"   <p>",
"    The effects of pregnancy on maternal renal disease and the effect of renal disease on the outcome of pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all patients, a major goal of treatment of hypertension is to minimize the risk of cardiovascular or cerebrovascular events. Untreated mild hypertension over the course of a pregnancy is unlikely to affect this risk. On the other hand, untreated severe hypertension, even over the short-term, may be associated with adverse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h4\">",
"     Mild to moderate chronic hypertension in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate chronic hypertension in pregnancy is defined as systolic BP 140 to 159 mmHg or diastolic 90 to 109 mmHg. This level of blood pressure corresponds most closely to stage 1 essential hypertension (defined as systolic 140 to 159 mmHg or diastolic 90 to 99 mmHg). The indications for initiating antihypertensive drugs in patients with mild to moderate hypertension in pregnancy without evidence of target organ damage who have not previously been treated or who have discontinued therapy are not clear. Neither the patient nor the fetus appears to be at risk from mildly elevated blood pressure during pregnancy (systolic &lt;150 mm Hg, diastolic &lt;100 mm Hg). It is not clear whether women with moderately elevated blood pressure levels (systolic BP 150 to 160 mmHg or diastolic 100 to 109 mmHg) have similar benign outcomes. Controlled trials, which have usually included women with both mild and moderate hypertension, have not demonstrated that lowering the blood pressure with antihypertensive medications reduces the risk of preeclampsia or abruption, or improves fetal or maternal outcome, although these studies have probably not had sufficient power to make definitive conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/3\">",
"     3",
"    </a>",
"    ]. It is clear from systematic reviews that therapy decreases the incidence of severe hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Eight to 13 women would need to be treated with an antihypertensive drug to prevent one episode of severe hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with chronic hypertension who are normotensive or mildly hypertensive on medication may continue their therapy or have their antihypertensive agents tapered",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stopped during pregnancy, with close monitoring of the maternal blood pressure response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1,7,29\">",
"     1,7,29",
"    </a>",
"    ]. There is no consensus on the best approach.",
"   </p>",
"   <p>",
"    Based on the available data, we avoid treatment of pregnant women with mild hypertension and no evidence of target organ damage, especially in the first trimester, since blood pressure normally decreases as pregnancy progresses into the second trimester. In women already on antihypertensive therapy who have early pregnancy blood pressures less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg, we would consider",
"    <span class=\"nowrap\">",
"     tapering/discontinuing",
"    </span>",
"    antihypertensive drugs and closely monitoring the blood pressure response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/29\">",
"     29",
"    </a>",
"    ]. Our indications for initiating or reinstituting antihypertensive therapy are persistent diastolic pressures of 95 to 99 mmHg, systolic pressures &ge;150 mmHg, or signs of hypertensive target-organ damage. These thresholds, although not in the severe range, allow nonemergent intervention with oral drugs while hypertension is only moderately elevated.",
"   </p>",
"   <p>",
"    These recommendations are similar to published guidelines from various national organizations. (See",
"    <a class=\"local\" href=\"#H16484005\">",
"     'Recommendations of selected national and international societies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h4\">",
"     Complicated and secondary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subgroups of women with mild to moderate hypertension appear to be at greater risk of maternal or fetal complications and may benefit from antihypertensive therapy. We suggest treatment of these women to attain blood pressures of 120 to",
"    <span class=\"nowrap\">",
"     140/80",
"    </span>",
"    to 90 mmHg; these recommendations are not based on data from randomized trials. These subgroups include women with [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Secondary, rather than essential, hypertension",
"     </li>",
"     <li>",
"      Target-organ damage (eg, left ventricular hypertrophy, microalbuminuria, retinopathy)",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Maternal age over 40 years old",
"     </li>",
"     <li>",
"      History of stroke",
"     </li>",
"     <li>",
"      Previous perinatal loss",
"     </li>",
"     <li>",
"      Diabetes (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"       \"Treatment of hypertension in patients with diabetes mellitus\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h4\">",
"     Severe hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypertension in pregnancy (blood pressure",
"    <span class=\"nowrap\">",
"     &ge;160/110",
"    </span>",
"    mmHg) corresponds most closely to the Joint National Committee (JNC) 7 definition of stage 2 hypertension in non-pregnant persons. This level of hypertension, particularly if associated with signs of early hypertensive encephalopathy, should be treated to protect the mother from serious complications, such as stroke, heart failure, or renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preference is to start treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    . A long-acting calcium channel blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) can be added as either second- or third-line treatment (",
"    <a class=\"graphic graphic_table graphicRef55212 \" href=\"UTD.htm?8/42/8875\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Blood pressure goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reasonable goal in women without target-organ damage is systolic pressure between 140 and 150 mmHg and diastolic pressure between 90 and 100 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. As discussed above, overly aggressive blood pressure reduction could be harmful. (See",
"    <a class=\"local\" href=\"#H53704432\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, in women with target-organ damage, it may be desirable to keep the blood pressure below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ]. Currently unresolved is whether lowering blood pressure to the \"normal\" range (ie,",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg) would confer either maternal or fetal benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other management issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antepartum assessment is directed toward early diagnosis of preeclampsia and fetal growth delay. This is best accomplished by frequent prenatal visits for monitoring maternal blood pressure, proteinuria, and fundal growth and by periodic sonographic estimation of fetal size [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h4\">",
"     Fetal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the role of antepartum fetal assessment in management of pregnancies complicated by mild maternal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. A baseline ultrasound examination at 16 to 20 weeks of gestation is recommended to confirm gestational age. This avoids uncertainty about a diagnosis of fetal growth delay versus incorrect estimation of the time of conception if a late pregnancy sonogram shows a small fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"     7",
"    </a>",
"    ]. In the absence of superimposed preeclampsia or fetal growth restriction, the need for, and frequency of, antepartum fetal assessment is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/16\">",
"     16",
"    </a>",
"    ]. Close fetal surveillance is warranted when there is a high potential for uteroplacental vasculopathy, as with superimposed preeclampsia or intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/16\">",
"     16",
"    </a>",
"    ]. In these cases, serial clinical assessment of fetal growth is indicated (ultrasound examination is an additional option at 28 to 32 weeks, then monthly until delivery), with twice weekly nonstress testing or biophysical profile examination, and Doppler velocimetry of the umbilical artery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h4\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials evaluating the optimum time for delivery in women with pre-existing hypertension. An expert consensus panel and the American College of Obstetricians and Gynecologists (ACOG) suggested the following approach for women with chronic hypertension: 38 to",
"    <span class=\"nowrap\">",
"     39",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks of gestation for women not requiring medication, 37 to",
"    <span class=\"nowrap\">",
"     39",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks for women with hypertension controlled with medication, and 36 to",
"    <span class=\"nowrap\">",
"     37",
"     <sup>",
"      6/7ths",
"     </sup>",
"    </span>",
"    weeks for women with severe hypertension difficult to control [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This recommendation was based, in part, from indirect evidence from the Hypertension and Preeclampsia Intervention Trial At Term (HYPITAT) trial in which women with gestational hypertension or mild preeclampsia had better maternal outcomes and equivalent neonatal outcomes with induction at &ge;37 weeks compared with expectant management [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/32\">",
"     32",
"    </a>",
"    ]. For women with superimposed preeclampsia or other pregnancy complications (eg, fetal growth restriction, previous stillbirth), the timing of delivery should be decided on a case-by-case basis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16484005\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF SELECTED NATIONAL AND INTERNATIONAL SOCIETIES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The United States National High Blood Pressure Education Program (NHBPEP) Working Group on High Blood Pressure in Pregnancy states that anti-hypertensive therapy is indicated for women with chronic hypertension and blood pressures exceeding 150 to 160 mmHg systolic or 100 to 110 mmHg diastolic or the presence of target organ damage (eg, renal insufficiency, left ventricular hypertrophy) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/1\">",
"       1",
"      </a>",
"      ]. They also recommend treatment of &ldquo;dangerously high&rdquo; blood pressure in women with preeclampsia; they do not define a specific level, but suggest a diastolic pressure greater than 100 to 110 mmHg be considered depending on patient-specific risk factors, such as baseline blood pressure.",
"     </li>",
"     <li>",
"      The Society of Obstetricians and Gynaecologists of Canada (SOGC) guideline recommends anti-hypertensive treatment for new onset systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;110 mmHg, with goal blood pressure",
"      <span class=\"nowrap\">",
"       &lt;160/110",
"      </span>",
"      mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/33\">",
"       33",
"      </a>",
"      ]. For women with chronic hypertension without comorbid conditions and blood pressure of 140 to",
"      <span class=\"nowrap\">",
"       159/90",
"      </span>",
"      to 109 mmHg, antihypertensive drug therapy should be used to keep systolic blood pressure at 130 to 155 mmHg and diastolic blood pressure at 80 to 105 mmHg. For women with chronic hypertension with comorbid conditions, antihypertensive drug therapy should be used to keep systolic blood pressure at 130 to 139 mmHg and diastolic blood pressure at 80 to 89 mmHg.",
"     </li>",
"     <li>",
"      The National Institute for Health and Clinical Excellence (",
"      <a class=\"external\" href=\"file://guidance.nice.org.uk/CG/Published\">",
"       NICE",
"      </a>",
"      ) recommends that for pregnant women with uncomplicated chronic hypertension the goal is to keep blood pressure lower than",
"      <span class=\"nowrap\">",
"       150/100",
"      </span>",
"      mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/34\">",
"       34",
"      </a>",
"      ]. In women with gestational hypertension or preeclampsia, treatment is initiated at blood pressures",
"      <span class=\"nowrap\">",
"       &ge;150/100",
"      </span>",
"      mmHg with the goal of systolic blood pressures &lt;150 mmHg and diastolic blood pressures of 80 to 100 mmHg. They also recommend use of low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      from 12 weeks of gestation to reduce the risk of preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link&amp;anchor=H9#H9\">",
"       \"Prevention of preeclampsia\", section on 'Approach to therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American College of Obstetricians and Gynecologists (ACOG) recommends treatment of severe hypertension and suggests",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      as first-line therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/16\">",
"       16",
"      </a>",
"      ]. They also suggest avoiding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      , angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers.",
"     </li>",
"     <li>",
"      The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC) recommends the following [",
"      <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/23\">",
"       23",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nonpharmacological management for pregnant women with systolic blood pressure of 140 to 150 mmHg or diastolic blood pressure of 90 to 99 mmHg",
"     </li>",
"     <li>",
"      In women with gestational hypertension or preexisting hypertension superimposed by gestational hypertension or with hypertension and subclinical organ damage or symptoms at any time during pregnancy, initiation of drug treatment is recommended at blood pressure of",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg. In any other circumstances, initiation of drug treatment is recommended if systolic blood pressure is &ge;150 mmHg or diastolic blood pressure is &ge;95 mmHg.",
"     </li>",
"     <li>",
"      Systolic blood pressure &ge;170 mmHg or diastolic blood pressure &ge;110 mmHg in a pregnant woman is an emergency, and hospitalization is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523716270\">",
"    <span class=\"h1\">",
"     POSTPARTUM HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum hypertension may be due to persistence of antepartum or intrapartum hypertension, or may be of new onset. Preeclampsia-related hypertension usually resolves spontaneously within a few weeks (average 16 &plusmn; 9.5 days) and is almost always gone by 12 weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, some cases may take as long as six months to resolve [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/35\">",
"     35",
"    </a>",
"    ]. Hypertension that persists beyond this period should be evaluated and treated as in any nonpregnant woman. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=see_link\">",
"     \"Hypertension: Who should be treated?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood pressure may be significantly higher in the immediate postpartum period than antepartum or intrapartum. This may be due to a combination of factors, including administration of a large volume of saline solution to women who have had a cesarean delivery or neuraxial anesthesia for labor, loss of pregnancy associated vasodilation after delivery, mobilization of extracellular fluid after delivery, and administration of non-steroidal antiinflammatory agents for postdelivery analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/37\">",
"     37",
"    </a>",
"    ]. Ergot derivatives, which are used to treat postpartum hemorrhage, also cause hypertension.",
"   </p>",
"   <p>",
"    Women with new onset postpartum hypertension should be evaluated by history (including review of postpartum medications and fluid balance) and physical examination. The presence of neurologic, cardiac, or gastrointestinal symptoms suggests a disorder other than transient hypertension related to fluids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New onset postpartum hypertension may be due to onset of preeclampsia or HELLP syndrome after delivery; these diagnoses are supported by laboratory evidence of proteinuria, low platelets,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal liver enzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary aldosteronism is a rare cause of postpartum hypertension. Women with this disorder may have lower blood pressure during pregnancy due to the natriuretic effects of progesterone, and may present with significant postpartum hypertension with or without hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link\">",
"     \"Clinical features of primary aldosteronism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523716301\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihypertensive agents may be required temporarily postpartum if hypertension is severe. We recommend initiating therapy if blood pressures are persistently greater than 140 mm Hg systolic at the time of discharge from the hospital. Oral medications similar to those used in the nonpregnant population can be prescribed, with modifications if the woman is breastfeeding. (See",
"    <a class=\"local\" href=\"#H53705226\">",
"     'Options for breastfeeding mothers'",
"    </a>",
"    above.) Brief",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    therapy (20 mg orally once or twice per day for five days) may facilitate return to normotension in women with severe, but not mild, preeclampsia, particularly those with significant edema [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/39\">",
"     39",
"    </a>",
"    ]. One guideline suggests avoiding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    postpartum because of the risk of postnatal depression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/7/13434/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood pressure should be monitored closely, ideally with evaluation in the patient's home after discharge, to avoid hypotension as the woman's blood pressure returns to her normal baseline level. If prepregnancy blood pressure was normal and the patient is not hypertensive on medication, it is reasonable to stop the antihypertensive agent after three weeks and monitor blood pressure to assess whether further treatment is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=see_link\">",
"       \"Patient information: Preeclampsia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       \"Patient information: High blood pressure and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"       \"Patient information: Preeclampsia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When hypertension is diagnosed in a pregnant woman, the major issues are establishing a diagnosis, deciding the blood pressure at which treatment should be initiated and the target blood pressure, and avoiding drugs that may adversely affect the fetus.",
"   </p>",
"   <p>",
"    In contrast to nonpregnant individuals in whom blood pressure is staged as normal, prehypertension, or stage 1 or 2, blood pressure in pregnant women is either normal, mild to moderate hypertension (140 to",
"    <span class=\"nowrap\">",
"     159/90",
"    </span>",
"    to 109 mmHg), or severe hypertension",
"    <span class=\"nowrap\">",
"     (&ge;160/110",
"    </span>",
"    mmHg).",
"   </p>",
"   <p>",
"    Treatment of severe hypertension has a well-established maternal benefit of reduction in stroke risk, but there is no proven maternal or fetal benefit from treatment of mild to moderate hypertension over the relatively short duration of a full term pregnancy. In addition, lowering maternal blood pressure can inhibit fetal growth by decreasing placental perfusion, and may expose the fetus to potentially harmful physiological effects of these drugs. (See",
"    <a class=\"local\" href=\"#H53704432\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) and direct renin inhibitors are contraindicated at all stages of pregnancy. &nbsp;(See",
"    <a class=\"local\" href=\"#H53705356\">",
"     'ACE inhibitors, ARBs, direct renin inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Preeclampsia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest avoiding antihypertensive therapy for mild to moderate hypertension associated with preeclampsia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There are no proven benefits to mother or fetus, other than reduction in risk of severe maternal hypertension, and we are concerned about potential adverse fetal effects. (See",
"      <a class=\"local\" href=\"#H53704432\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for antihypertensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment of severe hypertension (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The goal of treatment is to prevent maternal cerebrovascular complications. We initiate antihypertensive therapy in adult women at systolic pressures &ge;150 mmHg and diastolic blood pressures &ge;100 mmHg. We initiate treatment at a lower threshold in younger women whose baseline blood pressure was low, and in those with symptoms that may be attributable to elevated blood pressure (eg, headache, visual disturbances, chest discomfort).",
"      <br/>",
"      <br/>",
"      Other organizations, such as the American College of Obstetricians and Gynecologists (ACOG), have recommended treatment of hypertension when systolic blood pressure is &ge;160 mm Hg. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications for antihypertensive therapy'",
"      </a>",
"      above.) &nbsp;",
"      <br/>",
"     </li>",
"     <li>",
"      For acute blood pressure therapy, we recommend intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our target blood pressure goal is systolic pressure of 140 to 150 mmHg and diastolic pressure of 90 to 100 mmHg. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Target blood pressure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Chronic (preexistent) hypertension",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest avoiding treatment of uncomplicated mild to moderate essential hypertension (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There are no proven benefits to mother or fetus, other than reduction in risk of severe hypertension, and we are concerned about potential adverse effects on fetal growth. (See",
"      <a class=\"local\" href=\"#H53704432\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Mild to moderate chronic hypertension in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with uncomplicated essential hypertension already on antihypertensive therapy who have early pregnancy blood pressures less than",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg, we suggest",
"      <span class=\"nowrap\">",
"       tapering/discontinuing",
"      </span>",
"      antihypertensive drugs and closely monitoring the blood pressure response (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our indications for initiating or reinstituting antihypertensive therapy are persistent diastolic pressures of 95 to 99 mmHg, systolic pressures &ge;150 mmHg, or signs of hypertensive end-organ damage. These thresholds, although not in the severe range, allow nonemergent intervention with oral drugs while hypertension is only moderately elevated. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Mild to moderate chronic hypertension in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subgroups of women with mild hypertension appear to be at greater risk of maternal or fetal complications and may benefit from antihypertensive therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complicated and secondary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe hypertension (blood pressure",
"      <span class=\"nowrap\">",
"       &ge;160/110",
"      </span>",
"      mmHg) is treated to protect the mother from serious complications, such as stroke, heart failure, or renal failure. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Severe hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A long-acting calcium channel blocker (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ) can be added if needed. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Choice of drug'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The blood pressure goal in women without end-organ damage is systolic pressure 140 to 150 mmHg and diastolic pressure 90 to 100 mmHg. In women with end-organ damage, the goal is",
"      <span class=\"nowrap\">",
"       &lt;140/90",
"      </span>",
"      mmHg and as low as",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Blood pressure goal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53709705\">",
"    <span class=\"h2\">",
"     Postpartum hypertension",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure may be significantly higher in the immediate postpartum period than antepartum or intrapartum. This may be due to preeclampsia, intrapartum administration of a large volume of saline solution, loss of pregnancy associated vasodilation after delivery, mobilization of extracellular fluid after delivery, administration of non-steroidal antiinflammatory agents for postdelivery analgesia, or administration of ergot derivatives to treat postpartum hemorrhage. (See",
"      <a class=\"local\" href=\"#H523716270\">",
"       'Postpartum hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is indicated for severe hypertension and consideration should be given to initiating therapy before levels reach the severe range, especially since concerns regarding placental perfusion are no longer relevant. Oral medications similar to those used in the nonpregnant population can be prescribed, with modifications if the woman is breastfeeding. (See",
"      <a class=\"local\" href=\"#H523716301\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H53705226\">",
"       'Options for breastfeeding mothers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Working group report on high blood pressure in pregnancy. National Institutes of Health, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/2\">",
"      von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002; 24:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/3\">",
"      Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007; :CD002252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/4\">",
"      Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982; 1:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/5\">",
"      Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006; :CD001449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/6\">",
"      Peacock WF 4th, Hilleman DE, Levy PD, et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med 2012; 30:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/7\">",
"      Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002; 100:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/8\">",
"      Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/9\">",
"      Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003; :CD002863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/10\">",
"      Smith P, Anthony J, Johanson R. Nifedipine in pregnancy. BJOG 2000; 107:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/11\">",
"      Ahn HK, Nava-Ocampo AA, Han JY, et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens Pregnancy 2007; 26:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/12\">",
"      Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327:955.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Diagnosis and management of preeclampsia and eclampsia. ACOG practice bulletin #33. American College of Obstetricians and Gynecologists, Washington, DC 2002. Obstet Gynecol 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/14\">",
"      Committee on Obstetric Practice. Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia. Obstet Gynecol 2011; 118:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/15\">",
"      Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) 1985; 290:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/16\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 125: Chronic hypertension in pregnancy. Obstet Gynecol 2012; 119:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/17\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/18\">",
"      Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/19\">",
"      Boutroy MJ, Bianchetti G, Dubruc C, et al. To nurse when receiving acebutolol: is it dangerous for the neonate? Eur J Clin Pharmacol 1986; 30:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/20\">",
"      Schimmel MS, Eidelman AI, Wilschanski MA, et al. Toxic effects of atenolol consumed during breast feeding. J Pediatr 1989; 114:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/21\">",
"      Maloni JA. Lack of evidence for prescription of antepartum bed rest. Expert Rev Obstet Gynecol 2011; 6:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/22\">",
"      Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev 2005; :CD003514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/23\">",
"      European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/24\">",
"      Martin JN Jr, Thigpen BD, Moore RC, et al. Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure. Obstet Gynecol 2005; 105:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/25\">",
"      Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. Obstet Gynecol Surv 2010; 65:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/26\">",
"      Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/27\">",
"      Orbach H, Matok I, Gorodischer R, et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013; 208:301.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/28\">",
"      Bateman BT, Bansil P, Hernandez-Diaz S, et al. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol 2012; 206:134.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/29\">",
"      Nakhai-Pour HR, Rey E, B&eacute;rard A. Discontinuation of antihypertensive drug use during the first trimester of pregnancy and the risk of preeclampsia and eclampsia among women with chronic hypertension. Am J Obstet Gynecol 2009; 201:180.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/30\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/31\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/32\">",
"      Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374:979.",
"     </a>",
"    </li>",
"    <li>",
"     Magee LA, Helewa M, Moutquin JM, von Dadelszen P, Hypertension Guideline Committee, Society of Obstetricians and Gynaecologists of Canada. Treatment of the hypertensive disorders of pregnancy. In: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008 Mar;30(3 Suppl 1):S24-36. file://www.guideline.gov/content.aspx?id=13401 (Accessed on July 12, 2011).",
"    </li>",
"    <li>",
"     National Collaborating Centre for Women's and Children's Health. Hypertension in pregnancy. The management of hypertensive disorders during pregnancy. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Aug. 46 p. (Clinical guideline; no. 107). file://www.guideline.gov/content.aspx?id=24122.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/35\">",
"      Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy 2010; 29:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/36\">",
"      Sibai BM. Etiology and management of postpartum hypertension-preeclampsia. Am J Obstet Gynecol 2012; 206:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/37\">",
"      Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. Am J Obstet Gynecol 2004; 190:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/38\">",
"      Podymow, T, Brucculeri, M, August, P. Primary Hyperaldosteronism in Pregnancy: a Case Series. Hypertension in Pregnancy 2006; 25:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/7/13434/abstract/39\">",
"      Ascarelli MH, Johnson V, McCreary H, et al. Postpartum preeclampsia management with furosemide: a randomized clinical trial. Obstet Gynecol 2005; 105:29.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6815 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13434=[""].join("\n");
var outline_f13_7_13434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H198338085\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53704432\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53705179\">",
"      Antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53705301\">",
"      - Options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53705507\">",
"      Methyldopa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53705068\">",
"      Beta-blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53705077\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H29869708\">",
"      Hydralazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53705086\">",
"      Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53704941\">",
"      - Drugs to avoid in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53705356\">",
"      ACE inhibitors, ARBs, direct renin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53705365\">",
"      Nitroprusside",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53705226\">",
"      - Options for breastfeeding mothers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H198338096\">",
"      Activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53710442\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53706253\">",
"      MANAGEMENT OF COMMON HYPERTENSIVE DISORDERS DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Indications for antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Choice of drug and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Long-term oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Target blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic (preexistent) hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Maternal evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mild to moderate chronic hypertension in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complicated and secondary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Severe hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Blood pressure goal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other management issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Fetal evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16484005\">",
"      RECOMMENDATIONS OF SELECTED NATIONAL AND INTERNATIONAL SOCIETIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523716270\">",
"      POSTPARTUM HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523716301\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Chronic (preexistent) hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53709705\">",
"      Postpartum hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/37/603\" title=\"table 2\">",
"      Criteria for gestational HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/42/8875\" title=\"table 3\">",
"      Drug doses for oral treatment of hypertension in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=related_link\">",
"      Expectant management of severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4169?source=related_link\">",
"      Hypertension: Who should be treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/422?source=related_link\">",
"      Initial evaluation of the hypertensive adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28246?source=related_link\">",
"      Management of severe asymptomatic hypertension (hypertensive urgencies)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=related_link\">",
"      Patient information: Preeclampsia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_7_13435="PSI and mortality";
var content_f13_7_13435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PSI class and mortality in the Pneumonia PORT validation cohort",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mortality, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        No predictors",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        &le;70",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        71-90",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        91-130",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        &gt;130",
"       </td>",
"       <td>",
"        27.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PSI: Pneumonia Severity Index; PORT: Patient Outcomes Research Team.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fine MJ, Auble TE, Yealy DM. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13435=[""].join("\n");
var outline_f13_7_13435=null;
var title_f13_7_13436="Pysch Sx of SUDs";
var content_f13_7_13436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Substance-induced syndromes mimicking primary psychiatric symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Substance",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Associated symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Intoxication",
"      </td>",
"      <td class=\"subtitle2\">",
"       Withdrawal",
"      </td>",
"      <td class=\"subtitle2\">",
"       Chronic use",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Alcohol",
"       </p>",
"       <p>",
"        Sedative/hypnotics",
"       </p>",
"      </td>",
"      <td>",
"       Dysphoria",
"      </td>",
"      <td>",
"       <p>",
"        Psychosis",
"       </p>",
"       <p>",
"        Dysphoria",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Dysphoria",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stimulants (eg, cocaine, amphetamines)",
"      </td>",
"      <td>",
"       <p>",
"        Paranoia",
"       </p>",
"       <p>",
"        Psychosis",
"       </p>",
"       <p>",
"        Manic-like symptoms",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"      <td>",
"       Dysphoria",
"      </td>",
"      <td>",
"       <p>",
"        Paranoia",
"       </p>",
"       <p>",
"        Psychosis",
"       </p>",
"       <p>",
"        Dysphoria",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Marijuana",
"      </td>",
"      <td>",
"       <p>",
"        Paranoia",
"       </p>",
"       <p>",
"        Psychosis",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Dysphoria",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"      <td>",
"       Paranoia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hallucinogens (eg, LSD, PCP)",
"      </td>",
"      <td>",
"       <p>",
"        Paranoia",
"       </p>",
"       <p>",
"        Psychosis",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Psychosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Opiates",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Dysphoria",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Dysphoria",
"       </p>",
"       <p>",
"        Anxiety",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Center for Substance Abuse Treatment. Substance Abuse Treatment for Persons With Co-Occurring Disorders. Publication no. (SMA) 05-3922, DHHS, Substance Abuse and Mental Health Services Administration, Rockville, MD 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13436=[""].join("\n");
var outline_f13_7_13436=null;
var title_f13_7_13437="Incid LN mets superf esoph CA";
var content_f13_7_13437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of lymph node metastases in superficial esophageal cancers according to depth of invasion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"9\" width=\"11%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author,",
"        <br/>",
"        year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Histology",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Percent LN Mets,",
"        <br/>",
"        mucosal lesion",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Percent LN Mets,",
"        <br/>",
"        submucosal lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        M1",
"       </td>",
"       <td class=\"subtitle2\">",
"        M2",
"       </td>",
"       <td class=\"subtitle2\">",
"        M3",
"       </td>",
"       <td class=\"subtitle2\">",
"        SM1",
"       </td>",
"       <td class=\"subtitle2\">",
"        SM2",
"       </td>",
"       <td class=\"subtitle2\">",
"        SM3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endo M; 2000",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        61",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fujita H; 2001",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liu L; 2005",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Westerterp M; 2005",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eguchi T; 2006",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        464",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        54*",
"       </td>",
"       <td>",
"        54*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shimada H; 2006",
"       </td>",
"       <td>",
"        Squam",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ancona E; 2008",
"       </td>",
"       <td>",
"        <p>",
"         Adeno",
"        </p>",
"        <p>",
"         Squam",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         31",
"        </p>",
"        <p>",
"         67",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepesi,B; 2010",
"       </td>",
"       <td>",
"        Adeno",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        H&ouml;lscher A; 2011",
"       </td>",
"       <td>",
"        <p>",
"         Adeno",
"        </p>",
"        <p>",
"         Squam",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         121",
"        </p>",
"        <p>",
"         50",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LN: lymph node; Squam: squamous cell cancer; Adeno: adenocarcinoma; NR: not reported.",
"     <br/>",
"     * SM2/SM3 combined.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13437=[""].join("\n");
var outline_f13_7_13437=null;
var title_f13_7_13438="Discussing adolescent sexuality";
var content_f13_7_13438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested examples of developmentally appropriate ways to discuss adolescent sexuality and screen, counsel, and prevent sexually transmitted infections*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Developmental stage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Issue",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Early adolescence",
"        </p>",
"        10 to 14 years old",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Middle adolescence",
"        </p>",
"        15 to 17 years old",
"       </td>",
"       <td class=\"subtitle2\">",
"        <p>",
"         Late adolescence",
"        </p>",
"        &ge;18 years old",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Puberty",
"       </td>",
"       <td>",
"        <p>",
"         \"Has your mom/dad talked to you about puberty, and the way your body changes as you become a teenager?\"",
"        </p>",
"        <p>",
"         \"Do you have odor from your armpits and/or use deodorant now?\"",
"        </p>",
"        <p>",
"         \"Do you notice that your breasts/penis/testicles or balls are getting bigger?\"",
"        </p>",
"        <p>",
"         \"Have you experienced something coming out of your penis during the night? We call these nocturnal emissions and they are very normal.\"",
"        </p>",
"        <p>",
"         \"Most girls will get some discharge or fluid and mucous that comes out of the vagina which is normal and related to hormones.\"",
"        </p>",
"        \"Do you have any concerns about the changes your body is starting to go through?\"",
"       </td>",
"       <td>",
"        <p>",
"         \"It looks as if your body is finishing/finished puberty, but that does not mean you have finished all the other tasks and growing of puberty.\"",
"        </p>",
"        <p>",
"         \"Do you have any concerns about your body?\"",
"        </p>",
"        \"Do you like your body or do you have strong feelings about any particular body parts?\"",
"       </td>",
"       <td>",
"        <p>",
"         \"You have completed puberty but still have additional brain, social, and emotional growth ahead.\"",
"        </p>",
"        <p>",
"         \"How do you feel about where you are in your development?\"",
"        </p>",
"        <p>",
"         \"Do you feel confident and competent to make health decisions?\"",
"        </p>",
"        <p>",
"         \"Do you have questions about the social and emotional development that occurs as you leave for school or a job?\"",
"        </p>",
"        \"As you get older we will start doing regular breast or chest examinations and/or cervical pap screenings to check for or prevent cancer.\"",
"        <p>",
"         &nbsp;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Gender",
"       </td>",
"       <td>",
"        \"Most of us learn about being a girl or boy from early on. When you think about your brain and body, do you consider yourself a girl, a boy, somewhere in between? Are you happy and comfortable being a boy or girl, or do you have questions about your gender?\"",
"       </td>",
"       <td>",
"        <p>",
"         \"I ask all my patients when they come in for check-ups: 'Do you consider yourself a girl, boy, or somewhere in between? How do you describe your gender?'\"",
"        </p>",
"        \"There are lots of ways that people experience or express gender. I am open to discussing this or any questions about gender with you.\"",
"       </td>",
"       <td>",
"        <p>",
"         \"How do you identify, regarding gender? That is do you feel or regard yourself as a woman, man, or something in between, or some other way?\"",
"        </p>",
"        \"Do you have any questions or concerns about your gender?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Sexuality",
"       </td>",
"       <td>",
"        <p>",
"         \"Have you and your parent(s) talked about sex and how to make decisions about getting involved in a romantic or sexual relationship?\"",
"        </p>",
"        <p>",
"         \"What have you and your parent(s) talked about so far?\"",
"        </p>",
"        <p>",
"         \"If you were to have a crush or romantic feelings toward someone, would that someone be a girl, boy, both, or neither?\"",
"        </p>",
"        <p>",
"         \"Do you have someone that you like or that you would like to talk to or date?\"",
"        </p>",
"        <p>",
"         \"Do you have any questions about your sexuality?\"",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         \"Are you attracted to girls, boys, or both?\"",
"        </p>",
"        <p>",
"         \"Who have you been romantically and sexually involved with in the past?\"",
"        </p>",
"        <p>",
"         \"Have you ever had sex?\" (See specific questions related to types of sex below.)",
"        </p>",
"        <p>",
"         \"Do you feel safe with your partner(s)?\"",
"        </p>",
"        <p>",
"         \"What do you do for sexually transmitted infection protection?\"",
"        </p>",
"        <p>",
"         \"What do you use for pregnancy prevention?\"",
"        </p>",
"        \"What do you know or what would you like to know about birth control options?\"",
"       </td>",
"       <td>",
"        <p>",
"         \"Are you attracted to women, men, or both?\"",
"        </p>",
"        <p>",
"         \"Who have you been romantically or sexually involved with in the past?\"",
"        </p>",
"        <p>",
"         \"How many sexual partners have you ever had? What types of sexual behaviors have you tried or are currently having?\"",
"        </p>",
"        \"Does sex feel good and satisfying for you and your partner? Do you have any concerns about orgasm, ejaculation, or your sexual function?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Sexual behaviors",
"       </td>",
"       <td>",
"        <p>",
"         \"Do you have any questions about a common way some young people your age are sexually active, such as masturbation or touching yourself?\"",
"        </p>",
"        <p>",
"         \"What sorts of things have you been taught or heard about sex?\"",
"        </p>",
"       </td>",
"       <td>",
"        \"What kinds of sex have you had?",
"        <br/>",
"        <ul>",
"         <li>",
"          Kissing",
"         </li>",
"         <li>",
"          Petting or touching breasts",
"         </li>",
"         <li>",
"          Touching a penis to masturbate and make it cum",
"         </li>",
"         <li>",
"          Fingering or putting fingers in vagina or anus",
"         </li>",
"         <li>",
"          Putting your mouth on a penis or vagina",
"         </li>",
"         <li>",
"          Having someone put their mouth on your penis or vagina",
"         </li>",
"         <li>",
"          Putting your penis in a vagina or penis in an anus",
"         </li>",
"         <li>",
"          Having someone else put their penis in your anus?\"",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         \"What kinds of sex and partners do you have?\"",
"        </p>",
"        <p>",
"         \"Some people feel uncomfortable talking about sex. I hope this can be a safe and comfortable place for you to talk about sex.\"",
"        </p>",
"        \"There is a variety of ways to be sexually active. Do you have any questions about different ways to be sexual or have sex?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        STI prevention",
"       </td>",
"       <td>",
"        <p>",
"         \"Do you have any questions about how to be safe in a sexual relationship?\"",
"        </p>",
"        <p>",
"         \"What have you heard about ways to protect yourself if you do have sex?\"",
"        </p>",
"        <p>",
"         \"Do you know about condoms? How we use them? How they can help prevent pregnancy and sexually transmitted infections?\"",
"        </p>",
"        <p>",
"         \"What do you know about sexually transmitted infections?\"",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         \"What do you know about sexually transmitted infections?\"",
"        </p>",
"        <p>",
"         \"What do you know about how to protect yourself or a partner from sexually transmitted infections?\"",
"        </p>",
"        <p>",
"         \"Have you ever had: chlamydia, gonorrhea, genital warts, or herpes?\"",
"        </p>",
"        <p>",
"         \"Have you ever been tested for syphilis or HIV?\"",
"        </p>",
"        <p>",
"         \"What have your used or tried in order to prevent sexually transmitted infections?\"",
"        </p>",
"        <p>",
"         \"What has worked for you? What has not worked so well for you in the past?\"",
"        </p>",
"        \"Would you like testing for sexually transmitted infections today?\"",
"       </td>",
"       <td>",
"        <p>",
"         \"Are you currently having sex and/or in a relationship?\"",
"        </p>",
"        <p>",
"         \"Who do you have sex with?\"",
"        </p>",
"        <p>",
"         \"Have you and your partner discussed whether your relationship is monogamous or whether you both will also be having other sex partners?\"",
"        </p>",
"        <p>",
"         \"Are you feeling valued and respected in your relationship? Do you feel safe in your relationship?\"",
"        </p>",
"        <p>",
"         \"What would or could make your relationship better?\"",
"        </p>",
"        \"Until age 26, we recommend at least annual sexually transmitted infection testing; can we do this today?\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus.",
"     <br>",
"      * This is not meant to be a comprehensive list, but to provide examples of the developmental differences among early, middle, and late adolescents. Questions related to dating violence are discussed in the topics on date rape.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13438=[""].join("\n");
var outline_f13_7_13438=null;
var title_f13_7_13439="Complement pathways 2";
var content_f13_7_13439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Complement activation pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complement activation pathways and their regulators (in red) are depicted in this figure.",
"    <div class=\"footnotes\">",
"     DAF: delay accelerating factor; CR1: complement receptor 1; MCP: membrane cofactor protein; MAC: membrane attack complex; C1-est inhib: C1 esterase inhibitor; MBL: mannose binding lectin; MASP: mannose binding lectin associated proteases; C4bp: C4 binding protein; B: factor B; P: properdin.",
"     <br>",
"      * Factor H also acts as a cofactor for factor I to regulate the C3 and C5 convertases.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Noris M, Remuzzi G. Hemolytic Uremic Syndrome. J Am Soc Nephrol 2005; 16:1035. Copyright &copy;2005 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_7_13439=[""].join("\n");
var outline_f13_7_13439=null;
